The prediction of early preeclampsia: Results from a longitudinal proteomics study

Adi L. Tarca,1,2,3,*, Roberto Romero,1,4,5,6,*, Neta Benshalom-Tirosh,1,2, Nandor Gabor Than,1,7,8,*, Dereje W. Gudicha,1,2, Bogdan Done,1, Percy Pacora,1,2, Tinnakorn Chaiworapongs,1,2, Bogdan Panaitescu,1,2, Dan Tirosh,1,2, Nardhy Gomez-Lopez,1,2,10,11,*, Sorin Draghici,2,3, Sonia S. Hassan,1,2,12, Offer Erez,1,2,13

1 Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services (NICHD/NIH/DHHS), Bethesda, Maryland, and Detroit, Michigan, United States of America, 2 Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan, United States of America, 3 Department of Computer Science, Wayne State University College of Engineering, Detroit, Michigan, United States of America, 4 Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan, United States of America, 5 Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, Michigan, United States of America, 6 Center for Molecular Medicine and Genetics, Wayne State University, Detroit, Michigan, United States of America, 7 Systems Biology of Reproduction Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary, 8 First Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary, 9 Maternity Clinic, Kuvoligy Clinical Block, Semmelweis University, Budapest, Hungary, 10 C.S. Mott Center for Human Growth and Development, Wayne State University, Detroit, Michigan, United States of America, 11 Department of Biochemistry, Microbiology, and Immunology, Wayne State University School of Medicine, Detroit, Michigan, United States of America, 12 Department of Physiology, Wayne State University School of Medicine, Detroit, Michigan, United States of America, 13 Maternity Department "D," Division of Obstetrics and Gynecology, Soroka University Medical Center, School of Medicine, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel

* prbchiefstaff@med.wayne.edu (RR); atarca@med.wayne.edu (ALT)

Abstract

Objectives
To identify maternal plasma protein markers for early preeclampsia (delivery <34 weeks of gestation) and to determine whether the prediction performance is affected by disease severity and presence of placental lesions consistent with maternal vascular malperfusion (MVM) among cases.

Study design
This longitudinal case-control study included 90 patients with a normal pregnancy and 33 patients with early preeclampsia. Two to six maternal plasma samples were collected throughout gestation from each woman. The abundance of 1,125 proteins was measured using high-affinity aptamer-based proteomic assays, and data were modeled using linear mixed-effects models. After data transformation into multiples of the mean values for gestational age, parsimonious linear discriminant analysis risk models were fit for each gestational-age interval (8–16, 16.1–22, 22.1–28, 28.1–32 weeks). Proteomic profiles of early preeclampsia cases were also compared to those of a combined set of controls and late...
preeclampsia cases (n = 76) reported previously. Prediction performance was estimated via bootstrap.

Results
We found that 1) multi-protein models at 16.1–22 weeks of gestation predicted early preeclampsia with a sensitivity of 71% at a false-positive rate (FPR) of 10%. High abundance of matrix metalloproteinase-7 and glycoprotein IIbIIIa complex were the most reliable predictors at this gestational age; 2) at 22.1–28 weeks of gestation, lower abundance of placental growth factor (PIGF) and vascular endothelial growth factor A, isoform 121 (VEGF-121), as well as elevated sialic acid binding immunoglobulin-like lectin 6 (siglec-6) and activin-A, were the best predictors of the subsequent development of early preeclampsia (81% sensitivity, FPR = 10%); 3) at 28.1–32 weeks of gestation, the sensitivity of multi-protein models was 85% (FPR = 10%) with the best predictors being activated leukocyte cell adhesion molecule, siglec-6, and VEGF-121; 4) the increase in siglec-6, activin-A, and VEGF-121 at 22.1–28 weeks of gestation differentiated women who subsequently developed early preeclampsia from those who had a normal pregnancy or developed late preeclampsia (sensitivity 77%, FPR = 10%); 5) the sensitivity of risk models was higher for early preeclampsia with placental MVM lesions than for the entire early preeclampsia group (90% versus 71% at 16.1–22 weeks; 87% versus 81% at 22.1–28 weeks; and 90% versus 85% at 28.1–32 weeks, all FPR = 10%); and 6) the sensitivity of prediction models was higher for severe early preeclampsia than for the entire early preeclampsia group (84% versus 71% at 16.1–22 weeks).

Conclusion
We have presented herein a catalogue of proteome changes in maternal plasma proteome that precede the diagnosis of preeclampsia and can distinguish among early and late phenotypes. The sensitivity of maternal plasma protein models for early preeclampsia is higher in women with underlying vascular placental disease and in those with a severe phenotype.

Introduction
Preeclampsia is a major obstetrical syndrome [1–3], classified according to the time of its clinical manifestation as “early preeclampsia” if it occurs prior to 34 weeks of gestation and, otherwise, as “late preeclampsia” [4–10]. The 34-week cut-off is most commonly used [9,11,12] given the substantial decline in maternal [6,13–17] and neonatal [8,13,18–24] morbidity compared to later gestational ages.

Early preeclampsia accounts for approximately 10% of the cases [8], and its pathophysiology involves both maternal predisposing factors and disorders of deep placentation [25,26]. Indeed, in early preeclampsia, the frequency of placental vascular lesions consistent with maternal vascular malperfusion (MVM) is higher than in late preeclampsia [27–30], suggesting that the underlying pathological processes leading to this phenotype begin in the early stages of gestation and involve an angiogenic imbalance [11,31–37]. This finding has clinical implications given that patients identified to be at risk by the end of the first trimester can benefit from treatment [38–41].
Current prediction models for preeclampsia combine maternal risk factors, Doppler velocimetry of the uterine arteries, and maternal blood proteins [32,37,42–46]. Although the detection rate of these models [12,47–50] for the identification of patients at risk for early/preterm preeclampsia is sufficient to enable preventive strategies [40], the contribution of biochemical markers in these models is limited. Moreover, Doppler velocimetry required in the current screening models [47,51–57] to compensate for the sub-optimal prediction by biochemical markers may not be available in all clinical settings.

Therefore, we used a novel high-affinity aptamer-based proteomic platform to identify longitudinal changes in maternal plasma proteins that have the potential to improve prediction of early preeclampsia and to distinguish between the early and late phenotypes. We also investigated whether the predictive performance of protein markers is impacted by disease severity and the presence of placental lesions consistent with MVM among cases.

**Materials and methods**

**Study design**

A nested case-control study was conducted, including patients diagnosed with early preeclampsia (cases, n = 33) and those with a normal pregnancy (controls, n = 90). Women were enrolled as participants of a longitudinal cohort study conducted at the Center for Advanced Obstetrical Care and Research of the Perinatology Research Branch, NICHD/NIH/DHHS, the Detroit Medical Center, and Wayne State University. Women with a multiple gestation, severe chronic maternal morbidity (i.e., renal insufficiency, congestive heart disease, and/or chronic respiratory insufficiency), acute maternal morbidity (i.e., asthma exacerbation requiring systemic steroids and/or active hepatitis), or fetal chromosomal abnormalities and congenital anomalies were excluded from the study.

Plasma samples were collected at the time of each prenatal visit scheduled at four-week intervals from the first or early second trimester until delivery. All patients provided written informed consent prior to sample collection. The plasma proteome of each patient was profiled in two to six samples collected from each patient and included, for some of the cases, the sample collected after the diagnosis of early preeclampsia. Although data collected after diagnosis are displayed in longitudinal plots, all analyses reported herein were based only on samples collected prior to the diagnosis [median (interquartile range or IQR) of 3 (2–4) for cases and 2 (2–5) for controls].

The analysis presented in this manuscript is based on data and specimens collected under the protocol entitled “Biological Markers of Disease in the Prediction of Preterm Delivery, Preeclampsia and Intra-Uterine Growth Restriction: A Longitudinal Study.” The study was approved by the Institutional Review Boards of Wayne State University (WSU IRB#110605MP2F) and NICHD/NIH/DHHS (OH97-CH-N067).

**Clinical definitions**

Preeclampsia was defined as new-onset hypertension that developed after 20 weeks of gestation (systolic or diastolic blood pressure ≥140 mm Hg and/or ≥90 mm Hg, respectively, measured on at least two occasions, 4 hours to 1 week apart) and proteinuria (≥300 mg in a 24-hour urine collection, or two random urine specimens obtained 4 hours to 1 week apart containing ≥1+ by dipstick or one dipstick demonstrating ≥2+ protein) [58].

Early preeclampsia was defined as preeclampsia diagnosed and delivered before 34 weeks of gestation, and late preeclampsia was defined as preeclampsia delivered at or after 34 weeks of gestation [4]. Severe preeclampsia was diagnosed as preeclampsia with systolic blood pressure ≥160 mmHg, or diastolic blood pressure ≥110 mmHg, platelet count < 100,000 per
mm³, elevated liver enzymes, renal insufficiency, pulmonary edema or cyanosis, new-onset cerebral/visual disturbances, and/or right upper quadrant or epigastric pain [9,59].

**Histologic placental examination**

Placentas were examined according to standardized protocols by perinatal pathologists blinded to clinical diagnoses and obstetrical outcomes, as previously described [60]. Placental lesions were diagnosed using criteria established by the Perinatal Section of the Society for Pediatric Pathology [61] and the terminology was updated to be consistent with that recommended by the Amsterdam Placental Workshop Group consensus statement [62]. The definitions of lesions consistent with MVM were previously described [63].

**Proteomics analysis**

Maternal plasma protein abundance was determined by using the SOMAmer (Slow Off-rate Modified Aptamer) platform and reagents to profile 1,125 proteins [64,65]. Proteomics profiling services were provided by Somalogic, Inc. (Boulder, CO, USA). The plasma samples were diluted and then incubated with the respective SOMAmer mixes, and after following a suite of steps described elsewhere [64,65], the signal from the SOMAmer reagents was measured using microarrays.

**Statistical analysis**

Demographics data analysis. Clinical characteristics of the patient population were summarized as median and IQRs for continuous variables or as percentages for categorical variables. The comparison of demographic variables between the groups was performed using the Fisher’s exact test for binary variables and the Wilcoxon rank-sum test for continuous variables.

Proteomic data transformation. The raw protein abundance data consisted of relative fluorescence units obtained from scanning the microarrays with a laser scanner. A sample-by-sample adjustment in the overall signal within a single plate (85 samples processed per plate/ run) was performed in three steps: Hybridization Control Normalization, Median Signal Normalization, and Calibration, using the manufacturer’s protocol. Outlier values (larger than 2× the 98th percentile of all samples) were set to 2× the 98th percentile of all samples (data thresholding). Protein abundance was then log₂ transformed to improve normality. Linear mixed-effects models with cubic splines (number of knots = 3) were used to model protein abundance in the control group as a function of gestational age using the lme4 package [66] under the R statistical language and environment (www.r-project.org). Data for all samples were then expressed as multiple of the mean (MoM) values for the corresponding gestational age in the normal pregnancy group. Longitudinal protein abundance averages and confidence intervals in sub-groups (MVM vs non-MVM, and severe vs mild preeclampsia) were estimated using generalized additive mixed models implemented in the mgcv package and illustrated using ggplot2 package in R.

Development of multi-marker prediction models. To develop proteomics prediction models based on protein abundance collected in each gestational-age interval (8–16, 16.1–22, 22.1–28, 28.1–32, 32.1–36 weeks) and, at the same time, to obtain unbiased prediction performance estimates on the available dataset, we implemented advances in predictive modeling with omics data [67–69]. Log₂ MoM values for one protein at a time were used to fit a linear discriminant analysis (LDA) model and to compute by leave-one-out cross-validation, a classification performance measure for each protein. With leave-one-out cross-validation, data from one patient at a time is left out when fitting the LDA model, and then the fitted model is applied to the data of the subject left out. The resulting predictions were combined over all
patients to calculate prediction performance. The performance measure considered was the partial area under the curve (pAUC) of the receiver operating characteristic (ROC) curve (false-positive rate [FPR] < 50%). Proteins that failed to reach at least a 10% change in the average MoM value between the study groups were filtered out from the analysis. Next, LDA models were fit by using increasing sets of up to five of the top proteins ranked by the pAUC. To enforce model parsimony, the inclusion of each additional protein was conditioned on the increase of 0.01 units in the pAUC statistic.

To obtain an unbiased estimate of the prediction performance of multi-marker models, we used bootstrap (200 iterations). Each iteration involved the following steps: 1) draw a random sample with the replacement of 33 cases and 90 controls to create a training set and consider all patients not selected in the bootstrap sample as a test set; 2) apply all analytical steps involved in the prediction model development described above (including the selection of predictor proteins) for each gestational-age interval using the training set; 3) apply the resulting prediction model and determine its prediction performance on data from patients in the test set. The average performance over 200 test sets was reported as a robust estimate of the prediction performance. Alternatively, instead of creating training and test partitions via bootstrap, repeated (n = 67 times) 3-fold cross-validation was used to generate 201 training and test set pairs, while keeping all other parameters of the analysis the same as described above for bootstrap.

**Differential abundance analysis.** The classifier development pipeline described above identifies a parsimonious set of proteins that predict early preeclampsia, yet it will not necessarily retain all proteins showing evidence of differential abundance between groups. Therefore, a complementary analysis was performed to identify all proteins with significant differences in mean log2 MoM values between the cases and controls at each gestational-age interval. Linear models with coefficient significance evaluated via moderated t-tests were applied using the limma package [70] of Bioconductor [71]. Significance was inferred based on the FDR-adjusted p-value (q-value) < 0.1 after adjusting for body mass index, smoking status, maternal age, and parity.

Both prediction model development and differential abundance analyses described above were also applied, including only controls and early preeclampsia cases i) with placental MVM lesions and ii) those with a severe phenotype.

**Comparison between the proteomic profiles of early and late preeclampsia.** To identify protein changes specific to early onset, but not late onset, of the disease, data from the early preeclampsia (n = 33) group were compared to a combined group that included both late preeclampsia cases (N = 76) [72] and normal pregnancies (n = 90).

**Gene ontology and pathway analysis.** Proteins were mapped to Entrez gene identifiers [73] based on Somalogic, Inc. annotation and, subsequently, to gene ontology [74]. Biological processes over-represented among the proteins that changed with early preeclampsia were identified using a Fisher’s exact test. Gene ontology terms with three or more hits and a q-value < 0.1 were considered significantly enriched. Identification of signaling pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database [75] that were enriched in proteins with differential abundance was performed using a pathway impact analysis method previously described [76,77]. The analysis was conducted using the web-based implementation available in iPathwayGuide (http://www.advaitabio.com). All enrichment analyses used, as reference, the set of all 1,125 proteins that were profiled on the Somalogic platform.

**Results**

In the early preeclampsia group, 33% (11/33) of the women delivered a small-for-gestational-age neonate, 73% (24/33) had placental lesions consistent with MVM and 70% (23/33) were
severe cases. Cases were diagnosed from 24.6 to 33.4 weeks of gestation. Other characteristics of the study population classified by outcome and presence of placental MVM lesions are shown in Table 1.

**Proteomic prediction models for early preeclampsia by gestational age at blood draw**

The prediction performance indices of the multi-marker models involving up to five proteins were estimated by bootstrap and are illustrated in Fig 1 and Table 2. Fig 1 presents the sensitivity (10% FPR) of multi-marker models for early preeclampsia at each gestational-age interval.

At 8–16 weeks of gestation, multi-marker proteomics models predicted early preeclampsia with 31% sensitivity (FPR = 10%), which was higher than that of PlGF alone (17%). The importance of individual proteins in the prediction models was evaluated by the percentage of the 200 bootstrap iterations in which they were included in the best LDA prediction model. Matrix metalloproteinase 7 (MMP-7) and glycoprotein IIbIIIa (gpIIbIIIa) were chosen in the best model in 42% and 23% of the iterations, respectively, while high-mobility group protein 1 (HMG-1) and von Willebrand factor were selected in 10% of the iterations (Table 2). Individual patient longitudinal profiles of MMP-7 and gpIIbIIIa protein abundance are presented in Fig 2A and 2B, respectively.

At 16.1–22 weeks of gestation, multi-marker prediction models identified women at risk to develop early preeclampsia with a sensitivity of 71% (FPR = 10%) which was again higher than the estimate for PlGF alone (18%). MMP-7, gpIIbIIIa, and Soggy-1 were selected in the best model 90%, 18%, and 10% of the time, respectively. The longitudinal profiles of MMP-7 and gpIIbIIIa, emphasizing the differences in the samples taken between 16.1 to 22 weeks of gestation, are presented in Fig 2C and 2D.

At 22.1–28 weeks of gestation, the proteins most often selected in the best risk model for early preeclampsia out of 200 bootstrap iterations were sialic acid binding immunoglobulin-like lectin 6 (siglec-6) (58%), PlGF (52%), activin-A (25%), and VEGF121 (18%). Longitudinal profiles of these four proteins emphasizing the differences in the samples taken between 22.1 and 28 weeks of gestation are shown in Fig 3.

At 28.1–32 weeks of gestation, the bootstrap-estimated sensitivity of multi-marker risk models was 85% (FPR = 10%), with activated leukocyte cell-adhesion molecule (ALCAM), siglec-6, and VEGF121 being the most frequently selected markers (38%, 32%, and 32% of the bootstrap iterations, respectively). The longitudinal profiles of ALCAM are depicted in Fig 4.

Table 1. Demographic characteristics of the study population.

| Characteristic            | Normal pregnancy (n = 90) | Early PE (n = 33) |
|--------------------------|--------------------------|-------------------|
|                          | With MVM (n = 24)        | Without MVM (n = 9) |
| Gestational age at enrolment (weeks) | 9.1 (8.0–10.1) [p = 0.024] | 10.4 (8.3–15.2) [p = 0.042] |
| Gestational age at delivery (weeks) | 39.4 (39.0–40.4) [p < 0.001] | 31.2 (28.3–33.0) [p < 0.001] |
| Body mass index (kg/m²)    | 26.5 (22.8–33.2) [p = 0.27] | 26.3 (20.9–30.6) [p = 0.62] |
| Maternal age (years)       | 24 (21.0–27.8) [p = 0.05] | 22 (19.0–25.0) [p = 0.88] |
| Smoking status             | 18 (20%) [p = 1]         | 5 (20.83%) [p = 0.03] |
| Nulliparity                | 26 (28.9%) [p = 0.004]   | 15 (62.5%) [p = 0.44] |

Data are presented as median (interquartile range) or number (percentage); P-values are given for the comparison to the normal pregnancy group. Early PE: early preeclampsia; MVM: maternal vascular malperfusion.

https://doi.org/10.1371/journal.pone.0217273.t001
Fig 1. Sensitivity for early preeclampsia using multi-protein markers. Sensitivity (y-axis) at a 10% FPR are shown by gestational-age interval (x-axis) for early preeclampsia (PE), early PE with placental lesions consistent with MVM, and severe early PE. The vertical bars represent the average (with 95% confidence intervals) of sensitivity obtained from 200 bootstrap iterations. Early PE: early preeclampsia; FPR: false-positive rate; MVM: maternal vascular malperfusion.

https://doi.org/10.1371/journal.pone.0217273.g001

Of note, prediction performance estimates for early preeclampsia were slightly higher when estimated by repeated cross-validation (S1 Table) than by bootstrap (Table 2), yet the variance of the estimates with the former method was somewhat higher (data not shown). The most predictive proteins retained in the prediction models were similar between the two approaches (see Tables 2 and S1).
Prediction of early preeclampsia according to the presence of placental lesions consistent with maternal vascular malperfusion

To determine whether the sub-classification of early preeclampsia cases by placental lesions can lead to different protein markers and/or better prediction performance, a secondary analysis was performed that included the control group and only cases with placental lesions consistent with MVM. Bootstrap-based sensitivity estimates (at a fixed FPR of 10%) were higher for cases with MVM compared to those for the overall early preeclampsia group (16.1–22 weeks: 90% versus 71%; 22.1–28 weeks: 87% versus 81%; and 28.1–32 weeks: 90% versus 85%) (see bars in Fig 1 and Table 2).

In addition to a higher sensitivity for cases with placental MVM lesions compared to the overall early preeclampsia group, differences in the sets of best predictors also emerged at particular intervals of gestation (Table 2). For example, angiotensin-converting enzyme 2 (ACE2) at 8–16 weeks (see raw data in Fig 5) and siglec-6 at 22.1–32 weeks of gestation were more frequently selected as the best markers for early preeclampsia with MVM lesions than for overall early preeclampsia (see Table 2).

Prediction of early preeclampsia according to disease severity

When only severe early preeclampsia cases were included in the analysis and compared to normal pregnancy cases, the sensitivity of analysis (10% FPR) was significantly higher than for overall early preeclampsia (90% vs 71%) in the 16.1–22 week interval. At this gestational-age interval, but unlike early preeclampsia with MVM that was predicted mostly by an increase in MMP-7, the prediction for severe early preeclampsia also involved the increase in gpIbIIa for 14% of the models trained on bootstrap samples of the original dataset. Other differences in the set of best predictors for severe early preeclampsia compared to overall early preeclampsia were noted in the 8–16 weeks gestational-age interval (see Table 2).

Table 2. Summary of bootstrap results for prediction of early preeclampsia vs normal pregnancy.

| Outcome | Sample GA | AUC   | Sensitivity | Specificity | Predictor Symbols (% inclusion in best combination)          |
|---------|-----------|-------|-------------|-------------|-------------------------------------------------------------|
|         | (weeks)   |       |             |             |                                                             |
| 8–16    | 0.64      | 0.31  | 0.90        |             | MMP-7(42%), gpIbIIa(23%), HMG-1(10%), vWF(10%)              |
| All     | 16.1–22   | 0.88  | 0.71        | 0.90        | MMP-7(90%), gpIbIIa(18%), Soggy-1(10%),                      |
| Early PE| 22.1–28   | 0.90  | 0.81        | 0.90        | Siglec-6(58%), PlGF(52%), Activin A(25%), VEGF121(18%)     |
|         | 28.1–32   | 0.94  | 0.85        | 0.90        | ALCAM(38%), VEGF121(32%), Siglec-6(32%)                     |
| 8–16    | 0.63      | 0.32  | 0.90        |             | MMP-7(33%), gpIbIIa(26%), ACE2(18%)                        |
| Early PE| 16.1–22   | 0.96  | 0.90        | 0.90        | MMP-7(99%),                                                 |
| MVM     | 22.1–28   | 0.95  | 0.87        | 0.92        | Siglec-6(76%), PlGF(21%), Activin A(14%)                    |
|         | 28.1–32   | 0.95  | 0.90        | 0.90        | Siglec-6(63%), VEGF121(33%), ALCAM(10%)                     |
| 8–16    | 0.67      | 0.35  | 0.90        |             | MMP-7(44%), gpIbIIa(17%), Glutathione S-transferase Pi(12%), |
| Early PE| 16.1–22   | 0.94  | 0.84        | 0.90        | MMP-7(97%), gpIbIIa(14%)                                   |
| Severe  | 22.1–28   | 0.89  | 0.81        | 0.91        | Siglec-6(68%), PlGF(34%), VEGF121(24%), Activin A(14%)     |
|         | 28.1–32   | 0.95  | 0.88        | 0.90        | Siglec-6(52%), VEGF121(26%), ALCAM(22%)                    |

The number in parentheses following the name of each protein (column Predictor Symbols) represents the percentage of bootstrap iterations in which the protein was selected in the best model. Only proteins selected in 10% or more of the 200 bootstrap iterations are listed. ACE2: angiotensin converting enzyme 2; ALCAM: activated leukocyte cell adhesion molecule; AUC: area under the receiver operating characteristic curve; GA: gestational age; gpIbIIa: glycoprotein IIb/IIIa; HMG-1: high-mobility group protein 1; MMP: matrix metalloproteinase; early PE: early preeclampsia; MVM: maternal vascular malperfusion; PE: preeclampsia; PlGF: placental growth factor; Siglec-6: sialic acid binding immunoglobulin-like lectin; VEGF121: vascular endothelial growth factor A, isoform 121; vWF: von Willebrand factor; SMAC: Diablo homolog, mitochondrial; C4b: Complement C4b.

https://doi.org/10.1371/journal.pone.0217273.t002
Fig 2. Longitudinal maternal plasma abundance of MMP-7 and gpIIbIIIa in normal pregnancy and early preeclampsia. Each line corresponds to a single patient (grey = normal pregnancy, red = early preeclampsia). Individual dots represent samples at 8–16 weeks (A, B) and 16.1–22 weeks (C, D) of gestation. Samples taken at the time of diagnosis with early preeclampsia are marked with an “x” and were not included in the analysis but only displayed. The thick black line represents the mean value in normal pregnancy. AUC: area under the receiver operating characteristic curve of the protein using data in the current interval; early PE: early preeclampsia; FC: fold change; gpIIbIIIa: glycoprotein IIb/IIIa; MMP-7: matrix metalloproteinase 7; MoM: multiples of the mean; p: the nominal significance p-value comparing mean MoM values between groups with a moderate t-test. Log2FC is the log (base 2) of the fold change between the cases and control groups, with negative values denoting lower MoM values in cases than in controls.

https://doi.org/10.1371/journal.pone.0217273.g002
Fig 3. Longitudinal maternal plasma abundance of siglec-6 (A), PlGF (B), VEGF121 (C), and activin-A (D) in normal pregnancy and early preeclampsia cases, highlighting differences at 22.1–28 weeks. AUC: area under the receiver operating characteristic curve; early PE: early preeclampsia; FC: fold change; PlGF: placental growth factor; Siglec-6: sialic acid binding immunoglobulin-like lectin; VEGF121: vascular endothelial growth factor A, isoform 121.

https://doi.org/10.1371/journal.pone.0217273.g003
Proteomic markers that differentiate between early and late preeclampsia

Discrimination between early preeclampsia and both normal pregnancy and late preeclampsia was rather low in the 8-16-week and 16.1-22-week intervals (21% and 31% sensitivity, respectively, FPR = 10%) and involved different sets of proteins than those found when the comparison was only against the normal pregnancy group (Table 3). However, later in gestation, the sensitivity of multi-marker models to discriminate between early preeclampsia and both the controls and late preeclampsia increased to 77% and 82% at 16.1-22-week and 22.1-28-week intervals, respectively (FPR = 10%).

Fig 4. Longitudinal maternal plasma ALCAM abundance in normal pregnancy and early preeclampsia cases, highlighting differences at 28.1–32 weeks. ALCAM: activated leukocyte cell adhesion molecule; AUC: area under the receiver operating characteristic curve; early PE: early preeclampsia; FC: fold change; MVM: maternal vascular malperfusion.

https://doi.org/10.1371/journal.pone.0217273.g004

Proteomic markers that differentiate between early and late preeclampsia

Discrimination between early preeclampsia and both normal pregnancy and late preeclampsia was rather low in the 8-16-week and 16.1-22-week intervals (21% and 31% sensitivity, respectively, FPR = 10%) and involved different sets of proteins than those found when the comparison was only against the normal pregnancy group (Table 3). However, later in gestation, the sensitivity of multi-marker models to discriminate between early preeclampsia and both the controls and late preeclampsia increased to 77% and 82% at 16.1-22-week and 22.1-28-week intervals, respectively (FPR = 10%).
Of note, discriminating early preeclampsia from both normal pregnancy and late preeclampsia cases involved more stringent cut-offs for the same proteins (see Fig 6) and also new proteins such as ficolin 2 (FCN2) (see Table 3).

Differential protein abundance summary

In addition to the proteins included in the parsimonious models predictive of early preeclampsia at different gestational-age intervals (Table 2), other proteins (total, n = 175) had a significant differential abundance (after adjustment for body mass index, smoking status, maternal age, and parity) in at least one gestational-age interval (q-value < 0.1).


S2 Table presents the linear fold changes of MoM values between the early preeclampsia and normal pregnancy groups as well as the nominal and FDR-adjusted p-values (q-values) for each gestational-age interval. Additionally, the heatmap presented in Fig 7 summarizes the differential abundance patterns across all gestational-age intervals included in this study. There were 2, 37, 20, and 153 proteins associated with early preeclampsia at 8–16, 16.1–22, 22.1–28, and 28.1–32 weeks of gestation, respectively. MMP-7 was elevated in three of the four gestational-age intervals. IL-1 R4 (interleukin-1 receptor-like 1), siglec-6, and activin-A were elevated while FCN2, MMP-12, VEGF121, and PlGF were lower in all three intervals from 16.1 weeks of gestation onward. Differential abundance analyses were also summarized for early preeclampsia with MVM (S3 Table and S1 Table 3. Summary of bootstrap results for prediction of early preeclampsia versus normal pregnancy and late preeclampsia.

| Outcome | Sample GA (weeks) | AUC  | Sensitivity | Specificity | Predictor Symbols (% inclusion in best combination) |
|---------|-------------------|------|-------------|-------------|---------------------------------------------------|
| Early PE | 8–16              | 0.55 | 0.21        | 0.90        | gpIIbIIIa(34%)                                     |
| Early PE | 16.1–22           | 0.65 | 0.31        | 0.90        | Soggy-1(26%); IMDH2(20%); Siglec-6(14%); PKC-D(12%); MMP-12(10%); RBP(10%) |
| Early PE | 22.1–28           | 0.89 | 0.77        | 0.90        | Siglec-6(72%); Activin A(63%); VEGF121(34%)       |
| Early PE | 28.1–32           | 0.93 | 0.82        | 0.90        | Siglec-6(72%); ALCAM(15%); FCN2(14%); VEGF121(12%) |

ALCAM: activated leukocyte cell adhesion molecule; AUC: area under the receiver operating characteristic curve; early PE: early preeclampsia; FCN2: ficolin 2; GA: gestational age; gpIIbIIIa: glycoprotein IIb/IIIa; IMDH2: inosine-5’-monophosphate dehydrogenase (IMDH2); MMP: matrix metalloproteinase; PKC-D: protein kinase C delta type; RBP: retinol binding protein; Siglec-6: sialic acid binding immunoglobulin-like lectin; VEGF121: vascular endothelial growth factor A, isoform 121. Only proteins selected in 10% or more of the 200 bootstrap iterations are listed.

https://doi.org/10.1371/journal.pone.0217273.t003

Fig 6. Longitudinal maternal plasma abundance of siglec-6 (A) and activin-A (B) in normal pregnancy and early preeclampsia, highlighting differences at 22.1–28 weeks. Blue dots correspond to samples taken from late preeclampsia cases. AUC: area under the receiver operating characteristic curve; early PE: early preeclampsia; FC: fold change; late PE: late preeclampsia; Siglec-6: sialic acid binding immunoglobulin-like lectin.

https://doi.org/10.1371/journal.pone.0217273.g006
Biological processes and pathways perturbed in early preeclampsia during gestation

Gene ontology analysis of the proteins that changed significantly between patients with a normal pregnancy and those with early preeclampsia was performed for each gestational-age.
interval. At 16.1–22 weeks of gestation, there were 6; at 22.1–28 weeks, there were 7; and at 28.1–32 weeks, there were 30 biological processes significantly associated with early pre-eclampsia (Table 4). Biological processes associated with protein changes in at least one gestational age interval included cell adhesion, response to hypoxia, positive regulation of endothelial cell proliferation, extracellular matrix disassembly, and vascular endothelial growth factor receptor signaling pathway (all: q < 0.1) (Table 4).

No signaling pathways documented in the KEGG database [75] were found to be perturbed given the differential protein abundance observed in each interval of gestation.

Discussion
Principal findings of the study
The principal findings of the study are as follows: 1) At 16.1–22 weeks of gestation, multi-protein models predicted early preeclampsia with a sensitivity of 71% (FPR = 10%). The most reliable predictors in this interval were an elevated MMP-7 and gpIIbIIIa complex; 2) the best predictors of the subsequent development of early preeclampsia at 22.1–28 weeks of gestation were lower PlGF and VEGF121 as well as elevated siglec-6 and activin-A (81% sensitivity, FPR = 10%); 3) at 28.1–32 weeks of gestation, the sensitivity of multi-protein models was 85% (FPR = 10%) with the most reliable predictors being ALCAM, siglec-6, and VEGF121; 4) the increase in siglec-6, activin-A, and VEGF121 at 22.1–28 weeks of gestation differentiated women who subsequently developed early preeclampsia from those who had a normal pregnancy or late preeclampsia (sensitivity 77%, FPR = 10%); 5) the sensitivity of proteomic models for early preeclampsia in women with placental lesions consistent with MVM was higher than that of the models reported for the overall early preeclampsia group from 16.1 weeks of gestation onward; and 6) the sensitivity of prediction models was higher for severe early preeclampsia than for the entire early preeclampsia group (84% versus 71% at 16.1–22 weeks).

Of note, differential protein abundance results and, hence, downstream enrichment analyses are expected to vary among the different intervals of gestation due to several factors, such as: 1) differences in the sets of patients that contributed one sample in each interval, due to sample availability or to exclusion from analysis of samples at/or past the gestational age at diagnosis (see Methods); 2) differences in the magnitude of underlying disease-specific maternal plasma protein changes with preeclampsia; and 3) differences in the level of noise in the data, contributing non-biological variability.

Proteomics prediction models for the identification of patients with preeclampsia
Biomarkers for the identification of patients at risk for obstetrical syndromes such as small-for-gestational-age neonates [34,78–82], spontaneous preterm birth [83–94], fetal death [95–105], and preeclampsia [12,47,49,50,56,72,106–113] have been proposed. For preeclampsia, prediction models have evolved from ones that used maternal background characteristics alone (e.g., obstetrical history, chronic hypertension, familial history of preeclampsia, obesity) [114,115] to those that combine maternal demographic characteristics, obstetrical history [116,117], mean blood pressure [118], uterine artery Doppler studies [52,54,119], and molecular biomarkers [56,120–122] (e.g., PAPP-A [88,123–125] and inhibit-A [124,126–128]). Some of the most predictive biochemical markers include angiogenic and anti-angiogenic factors [33,129–134] (PlGF [34,135–137], sVEGFR-1 [138–142], and endoglin [143–148]), or their ratios [34,129,149–155]. A limitation of current screening methods for preeclampsia is the requirement of Doppler velocimetry, which is not readily available in middle- and low-
Table 4. Biological processes enriched in proteins with a differential abundance between early preeclampsia and normal pregnancy.

| Interval | Name                                                      | N  | OR   | p     | q     |
|----------|----------------------------------------------------------|----|------|-------|-------|
| 16.1–22 weeks | regulation of transcription from RNA polymerase II promoter | 3  | 9.5  | 0.007 | 0.0485 |
| 16.1–22 weeks | integrin-mediated signaling pathway                       | 3  | 7.3  | 0.014 | 0.071  |
| 16.1–22 weeks | extracellular matrix disassembly                          | 5  | 3.7  | 0.019 | 0.0838 |
| 16.1–22 weeks | response to hypoxia                                       | 3  | 5.1  | 0.031 | 0.0866 |
| 22.1–28 weeks | cell adhesion                                             | 5  | 3.3  | 0.033 | 0.0866 |
| 22.1–28 weeks | response to drug                                          | 4  | 3.7  | 0.036 | 0.0866 |
| 22.1–28 weeks | positive regulation of angiogenesis                       | 3  | 4.6  | 0.040 | 0.0866 |
| 22.1–28 weeks | extracellular matrix disassembly                          | 3  | 4.1  | 0.053 | 0.0976 |
| 28.1–32 weeks | blood coagulation                                        | 36 | 2.7  | 0.000 | 0.0042 |
| 28.1–32 weeks | platelet degranulation                                    | 18 | 3.9  | 0.000 | 0.0045 |
| 28.1–32 weeks | blood coagulation, intrinsic pathway                      | 8  | 8.9  | 0.000 | 0.0123 |
| 28.1–32 weeks | sprouting angiogenesis                                    | 6  | 13.1 | 0.000 | 0.0218 |
| 28.1–32 weeks | platelet activation                                      | 22 | 2.5  | 0.001 | 0.036  |
| 28.1–32 weeks | vascular endothelial growth factor signaling pathway      | 4  | 25.9 | 0.001 | 0.063  |
| 28.1–32 weeks | positive regulation of endothelial cell migration         | 7  | 5.8  | 0.002 | 0.0683 |
| 28.1–32 weeks | response to cold                                          | 3  | Inf  | 0.002 | 0.0703 |
| 28.1–32 weeks | plasminogen activation                                    | 3  | Inf  | 0.002 | 0.0703 |
| 28.1–32 weeks | nervous system development                                | 12 | 3.1  | 0.003 | 0.071  |
| 28.1–32 weeks | blood circulation                                         | 5  | 8.1  | 0.003 | 0.071  |
| 28.1–32 weeks | negative regulation of cell-substrate adhesion            | 4  | 13.0 | 0.004 | 0.071  |
| 28.1–32 weeks | positive regulation of macrophage activation              | 4  | 13.0 | 0.004 | 0.071  |
| 28.1–32 weeks | liver development                                         | 6  | 5.6  | 0.004 | 0.071  |
| 28.1–32 weeks | fibrinolysis                                              | 7  | 4.6  | 0.004 | 0.071  |
| 28.1–32 weeks | response to hypoxia                                       | 12 | 2.9  | 0.005 | 0.071  |
| 28.1–32 weeks | hematopoietic progenitor cell differentiation             | 4  | 8.6  | 0.008 | 0.086  |
| 28.1–32 weeks | response to vitamin D                                     | 4  | 8.6  | 0.008 | 0.086  |
| 28.1–32 weeks | negative regulation of fat cell differentiation           | 4  | 8.6  | 0.008 | 0.086  |
| 28.1–32 weeks | positive regulation of acute inflammatory response        | 3  | 19.3 | 0.009 | 0.086  |
| 28.1–32 weeks | cell-substrate junction assembly                           | 3  | 19.3 | 0.009 | 0.086  |
| 28.1–32 weeks | negative regulation of ossification                      | 3  | 19.3 | 0.009 | 0.086  |
| 28.1–32 weeks | negative regulation of B cell differentiation            | 3  | 19.3 | 0.009 | 0.086  |
| 28.1–32 weeks | cellular response to follicle-stimulating hormone stimulus | 3  | 19.3 | 0.009 | 0.086  |
| 28.1–32 weeks | negative regulation of angiogenesis                     | 7  | 3.8  | 0.009 | 0.086  |
| 28.1–32 weeks | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 7  | 3.8  | 0.009 | 0.086  |
| 28.1–32 weeks | positive regulation of neuron differentiation             | 6  | 4.4  | 0.010 | 0.0895 |
| 28.1–32 weeks | positive regulation of blood vessel endothelial cell migration | 5  | 5.4  | 0.010 | 0.0895 |
| 28.1–32 weeks | positive regulation of MAPK cascade                     | 9  | 3.0  | 0.011 | 0.0953 |

ID: Gene Ontology (GO) biological processes identifier; N: number of significant proteins assigned to the GO term; OR: odds ratio for enrichment; p: p-value; q: false discovery rate-adjusted p-value.

https://doi.org/10.1371/journal.pone.0217273.t004

resource populations. The detection rate for early preeclampsia drops to 77% and 57% at FPRs...
of 10% and 5%, respectively, in the absence of Doppler information [156]. Therefore, there would still be a benefit in developing accurate prediction models based solely on molecular information.

Discovery of molecular markers for obstetrical complications is often undertaken using "omics" technologies [157–165]: genomics [166,167], transcriptomics [168–175], proteomics [72,165,176–187], metabolomics [188–192], peptidomics [193–198], and lipidomics [199,200]. In particular, maternal proteomic profiles in preeclampsia were reported in maternal serum/plasma [175–177,180,201–210], urine [211–213], amniotic fluid [214,215], and the placenta [179,182,216–228]. However, most maternal plasma/serum proteomics studies to date did not involve samples collected longitudinally to determine how early molecular markers change their profiles prior to the disease onset and whether these changes are consistent throughout pregnancy, or the studies involved a small sample size.

The current study is one of the largest in this field and uses a new proteomics technology based on aptamers that allows the measurement of 1,125 proteins. Using this platform (SomaLogic, Inc.), we and other investigators reported the stereotypic longitudinal changes of the maternal plasma proteome in normal pregnancy [229,230] and late preeclampsia [72]. Our current report observing that an increased maternal plasma abundance of MMP-7 and gpIIbIIIa is predictive of early preeclampsia during the first half of pregnancy is novel.

Increased maternal plasma MMP-7 precedes diagnosis of preeclampsia

A possible explanation for the increased maternal plasma MMP-7 in preeclampsia is that it is a marker of abnormal placentation. MMP-7 is expressed in the decidua and trophoblast [231,232] and has been proposed to play a role in the process of transformation of the spiral arteries [233,234]. There is also histological evidence to support the involvement of MMP-7 in the processes associated with the development of preeclampsia [231] and early preeclampsia [233]. Additionally, MMP-7 can act as a sheddase for syndecan-1 [235,236], a major transmembrane heparan sulfate proteoglycan expressed on the surface (glycocalyx) of epithelial, endothelial, and syncytiotrophoblast cells [237–239], which are implicated in the pathophysiology of preeclampsia [240–243]. MMP-7 may also be involved in processes leading to the formation of atherosclerotic plaques [244] that show characteristics (e.g., lipid-laden macrophages) similar to acute atherosis of the spiral arteries associated with preeclampsia [245,246]. Of note in our previous study that used the same proteomics platform, MMP-7 was found to be a sensitive biomarker during the first half of pregnancy for the detection of patients who subsequently developed late preeclampsia [72]; herein, we showed that is also the case for early preeclampsia.

The role of glycoprotein IIbIIIa in early preeclampsia

To our knowledge, this is the first study to report that changes in the abundance of gpIIbIIIa in the maternal plasma are predictive of subsequent development of early preeclampsia. In this patient population, at 8–16 weeks of gestation, gpIIbIIIa performed better than PlGF (currently used to screen for preeclampsia) [48,50,51,137] for the detection of patients who subsequently developed early preeclampsia when profiled with the Somalogic platform (AUC = 0.60 for PlGF and 0.72 for gpIIbIIIa, see Table 2 and Fig 2B).

Glycoprotein IIb–IIIa is a membrane glycoprotein [247], the most common platelet receptor [247,248]. After a conformational change occurring during platelet activation [249], it interacts with ligands (e.g., von Willebrand factor and fibrinogen) to play a critical role in platelet aggregation and the cross-linkage of platelets into a hemostatic plug or thrombus [250–253]. Aspirin inhibits the expression of gpIIbIIIa by platelets [254]. This fact is important
given that aspirin is currently recommended by regulatory bodies in the United States for the prevention of preeclampsia [255–257]; moreover, this medication has recently been reported to reduce the rate of preterm preeclampsia by 62% [40]. Our findings suggest that gpIIbIIIa inhibitors could be further developed for the prevention of early preeclampsia.

**Presence of placental lesions of maternal vascular malperfusion and disease severity increases the sensitivity of proteomic models for early preeclampsia**

The sensitivity of the proteomic models at each gestational-age interval from 16.1 weeks onward was higher for cases that had placental lesions consistent with MVM than for the overall group of women with early preeclampsia and even compared to those with severe early preeclampsia. Maternal vascular malperfusion is a prevalent placental histologic finding in patients with early preeclampsia [28], and 73% (24/33) of cases in the current study had these lesions. These results further support a previous observation that the prediction performance of angiogenic index-1 (PIGF/sVEGFR-1) for preterm delivery (<34 weeks) is higher for women with these types of placental lesions [63].

Of interest, even when only patients with lesions consistent with MVM were compared to those with a normal pregnancy, proteins of placental origin (e.g., PIGF and siglec-6) were still the most predictive of early preeclampsia, but only after 22 weeks of gestation. This finding is consistent with our earlier study in late preeclampsia [72] and with previous longitudinal studies of angiogenic and anti-angiogenic factors [35,46,151]. Moreover, the data presented herein also support our previous systems biology study in early preeclampsia showing that siglec-6 expression in the placenta increased in the second half of pregnancy due to a hypoxic-ischemic trophoblastic response to placental malperfusion [258].

**Clinical implications**

The current study demonstrates the potential of maternal plasma protein changes to identify women at risk of early preeclampsia based on a single blood test. The use of disease-risk models based solely on proteomic markers would be similar to first- and second-trimester aneuploidy tests [259–262]. Such an approach can be implemented in various clinical settings, especially in low-resource areas, where Doppler velocimetry of the uterine arteries is not readily available. Moreover, the proteomics biomarkers identified in this study may assist in the introduction of novel therapeutic agents (e.g., gpIIbIIIa inhibitors) for the prevention of early preeclampsia.

**Strengths and limitations of the study**

The major strengths of this study are its longitudinal design, the number of patients and their stratification according to placental histology, and the large number of proteins tested. In addition, best practices in terms of model development and validation were based on our award-winning classifier development pipeline [67–69]. A limitation of this study is the fact that the aptamer-based assays did not include internal standards to generate protein concentrations (as opposed to fluorescence-based abundance); hence, further studies would be needed to generate protein concentration cut-offs. Additionally, the majority of the patients included in this study were of African-American lineage, and the generalization of findings to other ethnic groups needs to be further examined. Lastly, for three of the 33 early preeclampsia cases, the information regarding 24-hour proteinuria was not available; hence, we were reliant on dipstick evaluation.
Conclusions
Aptamer-based proteomic profiling of maternal plasma identified novel as well as previously known markers for early preeclampsia. At 16.1–22 weeks of gestation, more than two-thirds of patients who subsequently develop early preeclampsia can be identified by an elevated MMP-7 and gpIIbIIIA in maternal plasma (10% FPR). High abundance of siglec-6, VEGF121, and activin-A observed in the maternal circulation at 22.1–28 weeks of gestation was more specific to early rather than late preeclampsia. Proteomic markers were more sensitive for early preeclampsia cases with placental lesions consistent with MVM as well as those with a severe phenotype.

Supporting information
S1 Table. Summary of cross-validation results for prediction of early preeclampsia vs normal pregnancy. The number in parentheses following the name of each protein (column Predictor Symbols) represents the percentage of folds in which the protein was selected in the best model. Only proteins selected in 10% or more of the 3x67 = 201 folds are listed. ACE2: angiotensin converting enzyme 2; ALCAM: activated leukocyte cell adhesion molecule; AUC: area under the receiver operating characteristic curve; GA: gestational age; gpIIbIIIA: glycoprotein IIb/IIIa; HMG-1: high-mobility group protein 1; MMP: matrix metalloproteinase; early PE: early preeclampsia; MVM: maternal vascular malperfusion; PE: preeclampsia; PlGF: placental growth factor; Siglec-6: sialic acid binding immunoglobulin-like lectin; VEGF121: vascular endothelial growth factor A, isoform 121; vWF: von Willebrand factor.
(XLSX)

S2 Table. Summary of the differential abundance analysis between early preeclampsia and normal pregnancy in four intervals of gestation. List of 175 proteins with significantly different abundance between early preeclampsia and normal pregnancy (q < 0.1) in at least one interval, after adjustment for body mass index, maternal age, parity and smoking status. FC: linear fold change, with negative values denoting lower levels while positive values denote higher levels in cases than in controls.
(XLSX)

S3 Table. Summary of the differential abundance analysis between early preeclampsia and normal pregnancy in four intervals of gestation. List of 76 proteins with significantly different abundance between early preeclampsia with MVM and normal pregnancy (q < 0.1) in at least one interval, after adjustment for body mass index, maternal age, parity and smoking status. FC: linear fold change, with negative values denoting lower levels while positive values denote higher levels in cases than in controls.
(XLSX)

S4 Table. Summary of the differential abundance analysis between early preeclampsia and normal pregnancy in four intervals of gestation. List of 130 proteins with significantly different abundance between severe early preeclampsia and normal pregnancy (q < 0.1) in at least one interval, after adjustment for body mass index, maternal age, parity and smoking status. FC: linear fold change, with negative values denoting lower levels while positive values denote higher levels in cases than in controls.
(XLSX)

S1 File. Proteomics data used in the analyses presented in this study. Protein abundance data for each sample (rows) and each of the 1125 proteins is given in this table. Note, unlike for the early preeclampsia group, data for normal pregnancy group is the same as in [72],
and included in this file for convenience. ID: anonymized identifier indicator of the patient, GA: gestational age at sample, GADiagnosis: gestational age at diagnosis for cases; EarlyPE: is 1 for early preeclampsia and 0 for normal pregnancy. EarlyPE_MVM: is 1 for early preeclampsia with maternal vascular malperfusion and 0 for normal pregnancy or early preeclampsia without maternal vascular malperfusion; EarlyPE_Severe: is 1 for severe early preeclampsia cases; Protein symbol and names provided by Somalogic, Inc, are the same as S1 File in [72].

S1 Fig. Differential protein abundance analysis by generalized additive mixed models. Longitudinal differences in protein abundance assessed generalized additive mixed models are shown for proteins listed in Table 2. For each protein, differences are shown between early preeclampsia (PE) and controls (top left) as well as between mild or severe PE and controls (top right) and between PE with or without maternal vascular malperfusion (MVM) and controls. Thick lines show averages while grey bands give the 95% confidence interval.

Acknowledgments
We thank the physicians, nurses, and research assistants from the Center for Advanced Obstetrical Care and Research, Intrapartum Unit, PRB Clinical Laboratory, and PRB Perinatal Translational Science Laboratory for their help with collecting and processing samples.

Author Contributions
Conceptualization: Adi L. Tarca, Roberto Romero, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Offer Erez.
Data curation: Adi L. Tarca, Neta Benshalom-Tirosh, Percy Pacora, Tinnakorn Chaiworapongsa, Bogdan Panaitescu, Dan Tirosh.
Formal analysis: Adi L. Tarca, Dereje W. Gudicha, Bogdan Done.
Funding acquisition: Roberto Romero, Sonia S. Hassan.
Investigation: Adi L. Tarca, Roberto Romero, Nandor Gabor Than, Percy Pacora, Nardhy Gomez-Lopez, Sorin Draghici, Sonia S. Hassan, Offer Erez.
Methodology: Adi L. Tarca, Tinnakorn Chaiworapongsa.
Project administration: Adi L. Tarca, Sonia S. Hassan.
Resources: Roberto Romero.
Software: Adi L. Tarca, Sorin Draghici.
Supervision: Adi L. Tarca, Roberto Romero, Sonia S. Hassan, Offer Erez.
Validation: Adi L. Tarca.
Visualization: Adi L. Tarca.
Writing – original draft: Adi L. Tarca, Offer Erez.
Writing – review & editing: Adi L. Tarca, Roberto Romero, Neta Benshalom-Tirosh, Nandor Gabor Than, Percy Pacora, Tinnakorn Chaiworapongsa, Bogdan Panaitescu, Dan Tirosh, Nardhy Gomez-Lopez, Sorin Draghici, Sonia S. Hassan, Offer Erez.
References

1. Romero R (1996) The child is the father of the man. Prenat Neonat Med 1: 8–11.
2. Brosens I, Pijnenborg R, Vercruysse L, Romero R (2011) The “Great Obstetrical Syndromes” are associated with disorders of deep placentaion. Am J Obstet Gynecol 204: 193–201. https://doi.org/10.1016/j.ajog.2010.08.009 PMID: 21094932
3. Romero R, Lockwood C, Oyarzun E, Hobbins JC (1988) Toxemia: new concepts in an old disease. Semin Perinatol 12: 302–323. PMID: 3065943
4. von Dadelszen P, Magee LA, Roberts JM (2003) Subclassification of preeclampsia. Hypertens Pregnancy 22: 143–148. https://doi.org/10.1081/PRG-120021600 PMID: 12908998
5. Vatten LJ, Skjaerven R (2004) Is pre-eclampsia more than one disease? Bjog 111: 298–302. PMID: 15008762
6. Valensi H, Vasapollo B, Gagliardi G, Novelli GP (2008) Early and late preeclampsia: two different maternal hemodynamic states in the latent phase of the disease. Hypertension 52: 873–880. https://doi.org/10.1161/HYPERTENSIONAHA.108.117358 PMID: 18824660
7. Raymond D, Peterson E (2011) A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv 66: 497–506. https://doi.org/10.1097/OGX.0b013e3182331028 PMID: 22018452
8. Lisonkova S, Joseph KS (2013) Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol 209: 544.e541-544.e512.
9. Tranquilli AL, Brown MA, Zeeman GG, Dekker G, Sibai BM (2013) The definition of severe and early-onset preeclampsia. Statements from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Pregnancy Hypertens 3: 44–47. https://doi.org/10.1016/j.preghy.2012.11.001 PMID: 26105740
10. Verloren S, Melchiorre K, Khalil A, Thilaganathan B (2014) Uterine artery Doppler, birth weight and timing of onset of pre-eclampsia: providing insights into the dual etiology of late-onset pre-eclampsia. Ultrasound Obstet Gynecol 44: 293–298. https://doi.org/10.1002/uog.13310 PMID: 24448891
11. Soto E, Romero R, Kusanovic JP, Ogge G, Hussein Y, Yeo L, et al. (2012) Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med 25: 498–507. https://doi.org/10.3109/14767058.2011.591461 PMID: 21867402
12. Parra-Cordero M, Rodrigo R, Barja P, Bosco C, Rencoret G, Sepulveda-Martinez A, et al. (2013) Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy. Ultrasound Obstet Gynecol 41: 538–544. https://doi.org/10.1002/uog.12264 PMID: 22807133
13. Kucukgoz Gulec U, Ozgunen FT, Buyukkurt S, Guzel AB, Urunsak IF, Demir SC, et al. (2013) Comparison of clinical and laboratory findings in early- and late-onset preeclampsia. J Matern Fetal Neonatal Med 26: 1228–1233. https://doi.org/10.3109/14767058.2013.776535 PMID: 23413799
14. Lisonkova S, Sabr Y, Mayer C, Young C, Skoll A, Joseph KS (2014) Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet Gynecol 124: 771–781. https://doi.org/10.1097/AOG.0000000000000472 PMID: 25198279
15. Veerbeek JH, Hermes W, Breimer AY, van Rijn BB, Kooistra SV, Mol BW, et al. (2015) Cardiovascular disease risk factors after early-onset preeclampsia, late-onset preeclampsia, and pregnancy-induced hypertension. Hypertension 65: 600–606. https://doi.org/10.1161/HYPERTENSIONAHA.114.04850 PMID: 25561694
16. Bokslag A, Teunissen PW, Fransen C, van Kesteren F, Kamp O, Ganzevoort W, et al. (2017) Effect of early-onset preeclampsia on cardiovascular risk in the fifth decade of life. Am J Obstet Gynecol 216: 523.e521-523.e527.
17. Christensen M, Kronborg CS, Carlsen RK, Eldrup N, Knudsen UB (2017) Early gestational age at preeclampsia onset is associated with subclinical atherosclerosis 12 years after delivery. Acta Obstet Gynecol Scand 96: 1084–1092. https://doi.org/10.1111/aogs.13173 PMID: 28542803
18. Jelin AC, Cheng YW, Shaffer BL, Kaimal AJ, Little SE, Caughey AB (2010) Early-onset preeclampsia and neonatal outcomes. J Matern Fetal Neonatal Med 23: 389–392. https://doi.org/10.1080/14767050903168416 PMID: 19670045
19. Kovo M, Schreiber L, Ben-Haroush A, Gold E, Golan A, Bar J (2012) The placental component in early-onset and late-onset preeclampsia in relation to fetal growth restriction. Prenat Diagn 32: 632–637. https://doi.org/10.1002/pdi.3872 PMID: 22666486
20. Stuber J, Ullmann S, Dieterich M, Diedrich D, Reimer T (2014) Clinical differences between early- and late-onset severe preeclampsia and analysis of predictors for perinatal outcome. J Perinat Med 42: 617–627. https://doi.org/10.1515/jpm-2013-0285 PMID: 24778345
21. Madazli R, Yuksel MA, Imamoglu M, Tuten A, Oncul M, Aydin B, et al. (2014) Comparison of clinical and perinatal outcomes in early- and late-onset preeclampsia. Arch Gynecol Obstet 290: 53–57. https://doi.org/10.1007/s00404-014-3176-x PMID: 24549271

22. Khodzhaeva ZS, Kogan YA, Shmakov RG, Klimenchenko NI, Akatyeva AS, Vavina OV, et al. (2016) Clinical and pathogenetic features of early- and late-onset pre-eclampsia. J Matern Fetal Neonatal Med 29: 2980–2986. https://doi.org/10.3109/14767058.2015.111332 PMID: 26527472

23. Mor O, Stavsky M, Yitshak-Sade M, Mastrolia SA, Beer-Weisel R, Rafaeli-Yehudai T, et al. (2016) Early onset preeclampsia and cerebral palsy: a double hit model? Am J Obstet Gynecol 214: 105.e101–109.

24. Iacobelli S, Bonsante F, Robillard PY (2017) Comparison of risk factors and perinatal outcomes in early onset and late onset preeclampsia: A cohort based study in Reunion Island. J Reprod Immunol 123: 12–16. https://doi.org/10.1016/j.jri.2017.08.005 PMID: 28858635

25. Moldenhauer JS, Stanek J, Warshak C, Khoury J, Siabi B (2003) The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. Am J Obstet Gynecol 189: 1173–1177. PMID: 14586374

26. van der Merwe JL, Hall DR, Wright C, Schubert P, Grove D (2010) Are early and late preeclampsia distinct subclasses of the disease—what does the placenta reveal? Hypertens Pregnancy 29: 457–467. https://doi.org/10.3109/10641950903572282 PMID: 20701467

27. Sebire NJ, Goldin RD, Regan L (2005) Term preeclampsia is associated with minimal histopathological placental features regardless of clinical severity. J Obstet Gynaecol 25: 117–118. https://doi.org/10.1080/144361050041396 PMID: 15814385

28. Ogge G, Chaiworapongsa T, Romero R, Hussein Y, Kusanovic JP, Yeo L, et al. (2011) Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. J Perinat Med 39: 641–652. https://doi.org/10.1515/JPM.2011.096 PMID: 21848483

29. Redman CW, Sargent IL, Staff AC (2014) IFPA Senior Award Lecture: making sense of pre-eclampsia—two placental causes of preeclampsia? Placenta 35 Suppl: S20–25.

30. Nelson DB, Ziadie MS, McIntire DD, Rogers BB, Leveno KJ (2014) Placental pathology suggesting that preeclampsia is more than one disease. Am J Obstet Gynecol 210: 66.e61-67.

31. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649–658. https://doi.org/10.1172/JCI17189 PMID: 12618519

32. Lindheimer MD, Romero R (2007) Emerging roles of antiangiogenic and angiogenic proteins in pathogenesis and prediction of preeclampsia. Hypertension 50: 35–36. https://doi.org/10.1161/HYPERTENSIONAHA.107.089045 PMID: 17515451

33. Vatten LJ, Eskild A, Nileen TI, Jeansson S, Jenum PA, Staff AC (2007) Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 196: 239.e231-236.

34. Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, et al. (2008) The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 21: 279–287. https://doi.org/10.1080/14767050802034545 PMID: 18446652

35. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, et al. (2008) A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 21: 9–23. https://doi.org/10.1080/14767050719304795 PMID: 18175241

36. Gotsch F, Romero R, Kusanovic JP, Chaiworapongs T, Dombrowski M, Erez O, et al. (2008) Pre-eclampsia and small-for-gestational age are associated with decreased concentrations of a factor involved in angiogenesis: soluble Tie-2. J Matern Fetal Neonatal Med 21: 389–402. https://doi.org/10.1080/14767050802048069 PMID: 18570117

37. Vaisbuch E, Whitty JE, Hassan SS, Romero R, Kusanovic JP, Cotton DB, et al. (2011) Circulating angiogenic and antiangiogenic factors in women with eclampsia. Am J Obstet Gynecol 204: 152.e151-159.

38. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. (2010) Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 116: 402–414. https://doi.org/10.1097/AOG.0b013e3181e322a PMID: 20664402

39. Baschat AA (2015) First-trimester screening for pre-eclampsia: moving from personalized risk prediction to prevention. Ultrasound Obstet Gynecol 45: 119–129. https://doi.org/10.1002/ug.14770 PMID: 25627093
40. Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, et al. (2017) Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med 377: 613–622. https://doi.org/10.1056/NEJMoa1704559 PMID: 28657417

41. Groom KM, David AL (2018) The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction. Am J Obstet Gynecol 218: S829–s840. https://doi.org/10.1016/j.ajog.2017.11.565 PMID: 29239321

42. Stampalija T, Chaiworaopangs T, Romero R, Korzeniewski SJ, Schwartz AG, et al. (2013) Maternal plasma concentrations of sST2 and angiogenic/anti-angiogenic factors in preeclampsia. J Matern Fetal Neonatal Med 26: 1359–1370. https://doi.org/10.3109/14767058.2013.784256 PMID: 23488689

43. Baschat AA, Magder LS, Doyle LE, Atlas RO, Jenkins CB, Blitzer MG (2014) Prediction of preeclampsia utilizing the first trimester screening examination. Am J Obstet Gynecol 211: 514.e511-517.

44. Gallo DM, Wright D, Casanova C, Campanero M, Nicolaides KH (2016) Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19–24 weeks’ gestation. Am J Obstet Gynecol 214: 619 e611-619 e617.

45. Tsiakkas A, Saiid Y, Wright A, Wright D, Nicolaides KH (2016) Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30–34 weeks’ gestation. Am J Obstet Gynecol 215: 87 e81-87 e17.

46. Romero R, Chaemsaitong P, Tarca AL, Korzeniewski SJ, Maimon E, Pacora P, et al. (2017) Maternal plasma-soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia—a longitudinal study. J Matern Fetal Neonatal Med: 1–15.

47. Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH (2013) Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 33: 8–15. https://doi.org/10.3109/14767058.2013.784256 PMID: 23906160

48. Myers JE, Kenny LC, McCowan LM, Chan EH, Dekker GA, Poston L, et al. (2013) Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. Bjog 120: 1215–1223. https://doi.org/10.1111/1471-0528.12195 PMID: 22906914

49. O’Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, et al. (2016) Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11–13 weeks gestation. Am J Obstet Gynecol 214: 103.e101-103.e112.

50. Crovettos F, Figueras F, Triunfo S, Crispi F, Rodriguez-Sureda V, Dominguez C, et al. (2015) First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors. Prenat Diagn 35: 183–191. https://https://doi.org/10.1002/pd.4519

51. Espinoza J, Romero R, Nien JK, Gomez R, Kusanovic JP, Goncalves LF, et al. (2007) Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 196: 326.e321-313.

52. Crispi F, Llurba E, Dominguez C, Martin-Gallan P, Cabero L, Gratacos E (2008) Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 31: 303–309. https://doi.org/10.1002/ug.5184 PMID: 18058842

53. Melchiorre K, Worland B, Leslie K, Bhide A, Thilaganathan B (2008) First-trimester uterine artery Doppler indices in term and preterm pre-eclampsia. Ultrasound Obstet Gynecol 32: 133–137. https://doi.org/10.1002/ug.5400 PMID: 18615872

54. Llurba E, Carreras E, Gratacos E, Juan M, Astor J, Vives A, et al. (2009) Maternal history and uterine artery Doppler in the assessment of risk for development of early- and late-onset preeclampsia and intrauterine growth restriction. Obstet Gynecol Int 2009: 275613. https://doi.org/10.1155/2009/275613 PMID: 19936122

55. Poon LC, Staboulian I, Maiz N, Plasencia W, Nicolaides KH (2009) Hypertensive disorders in pregnancy: screening by uterine artery Doppler at 11–13 weeks. Ultrasound Obstet Gynecol 34: 142–148. https://doi.org/10.1002/ug.6452 PMID: 19644947

56. Audibert F, Boucoiran I, An N, Aleksandrovn A, Delvon E, Bujoel D, et al. (2010) Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynecol 203: 383.e381-388.

57. Ventura W, De Paco Matallana C, Prieto-Sanchez MT, Macizo MI, Pertegeal M, Nieto A, et al. (2015) Uterine and umbilical artery Doppler at 28 weeks for predicting adverse pregnancy outcomes in women with abnormal uterine artery Doppler findings in the early second trimester. Prenat Diagn 35: 294–298. https://doi.org/10.1002/pd.4542 PMID: 25483940

58. (2002) ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 99: 159–167. PMID: 16175681
59. Chaiworapongs T, Chaemsaithong P, Yeo L, Romero R (2014) Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol 10: 466–480. https://doi.org/10.1038/nrneph.2014.102 PMID: 25003615

60. Romero R, Kim YM, Pacora P, Kim CJ, Benshalom-Tirosh N, Jaiman S, et al. (2018) The frequency and type of placental histologic lesions in term pregnancies with normal outcome. J Perinat Med 46: 613–630. https://doi.org/10.1515/jpm-2018-0055 PMID: 30044764

61. Redline RW, Heller D, Keating S, Kingdom J (2005) Placental diagnostic criteria and clinical correlation—a workshop report. Placenta 26 Suppl A: S114–117.

62. Khong TY, Mooney EE, Ariel I, Balmus NC, Boyd TK, Brundler MA, et al. (2016) Sampling and Definitions of Placental Lesions: Amsterdam Placental Workshop Consensus Statement. Arch Pathol Lab Med 140: 698–713. https://doi.org/10.1043/1550-2696-CC PMID: 27223167

63. Redline RW, Heller D, Kingdom J (2005) Placental diagnostic criteria and clinical correlation—a workshop report. Placenta 26 Suppl A: S114–117.

64. Khong TY, Mooney EE, Ariel I, Balmus NC, Boyd TK, Brundler MA, et al. (2016) Sampling and Definitions of Placental Lesions: Amsterdam Placental Workshop Consensus Statement. Arch Pathol Lab Med 140: 698–713. https://doi.org/10.1043/1550-2696-CC PMID: 27223167

65. Davies DR, Gelinas AD, Zhang C, Rohloff JC, Carter JD, O’Connell D, et al. (2012) Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets. Proc Natl Acad Sci U S A 109: 19971–19976. https://doi.org/10.1073/pnas.1213933109 PMID: 23139410

66. Bates D, Maechler M, Bolker B, Walker S (2014) lme4: Linear mixed-effects models using Eigen and S4. http://arxiv.org/abs/1406.5823

67. Tarca AL, Than N. G., Romero R. (2013) Methodological approach from the Best Overall Team in the sbv IMPROVER Diagnostic Signature Challenge. Systems Biomedicine 1: 217–227.

68. Tarca AL, Lauria M, Unger M, Bilal E, Boue S, Kumar Dey K, et al. (2013) Strengths and limitations of microarray-based phenotype prediction: lessons learned from the IMPROVER Diagnostic Signature Challenge. Bioinformatics 29: 2892–2899. https://doi.org/10.1093/bioinformatics/btt492 PMID: 23966112

69. Dayarian A, Romero R, Wang Z, Biehl M, Bilal E, Hormoz S, et al. (2014) Predicting protein phosphorylation from gene expression: top methods from the IMPROVER Species Translation Challenge. Bioinformatics: 462–470. https://doi.org/10.1093/bioinformatics/btu490 PMID: 25061067

70. Smyth GK (2012) Limma: linear models for microarray data. In: Gentleman R, Carey VJ, Huber W, Irizarry RA, Dudoit S, editors. Bioinformatics and Computational Biology Solutions Using R and Bioconductor: Springer. pp. 397–420.

71. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. (2004) Bioconductor: open source development for computational biology and bioinformatics. Genome Biol 5: R80. https://doi.org/10.1186/gb-2004-5-10-r80 PMID: 15461798

72. Erez O, Romero R, Maymon E, Chaemaithong P, Don B, Pacora P, et al. (2017) The prediction of late-onset preeclampsia: Results from a longitudinal proteomics study. PLoS One 12: e0181468. https://doi.org/10.1371/journal.pone.0181468 PMID: 28738067

73. Maglott D, Ostell J, Pruitt KD, Tatusova T (2005) Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res 33: D54–58. https://doi.org/10.1093/nar/gki031 PMID: 15608257

74. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25–29. https://doi.org/10.1038/75556 PMID: 10802651

75. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M (1999) KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 27: 29–34. https://doi.org/10.1093/nar/27.1.29 PMID: 9847135

76. Draghici S, Khatri P, Tarca AL, Amin K, Done A, Voicita C, et al. (2007) A systems biology approach for pathway level analysis. Genome Res 17: 1537–1545. https://doi.org/10.1101/gr.6202607 PMID: 17785539

77. Tarca AL, Draghici S, Khatri P, Hassan SS, Mittal P, Kim JS, et al. (2009) A novel signaling pathway impact analysis. Bioinformatics 25: 75–82. https://doi.org/10.1093/bioinformatics/btn577 PMID: 18990722

78. Bobrow CS, Holmes RP, Muttukrishna S, Mohan A, Groome N, Murphy DJ, et al. (2002) Maternal serum activin A, inhibin A, and follistatin in pregnancies with appropriately grown and small-for-gestational-age fetuses classified by umbilical artery Doppler ultrasound. Am J Obstet Gynecol 186: 283–287. PMID: 11854651
79. Melchiorre K, Leslie K, Perfumo F, Bhide A, Thilaganathan B (2009) First-trimester uterine artery Doppler indices in the prediction of small-for-gestational age pregnancy and intravascular growth restriction. Ultrasound Obstet Gynecol 33: 524–529. https://doi.org/10.1002/uog.6368 PMID: 19382287

80. Karagianni G, Akolekar R, Sarquis R, Wright D, Nicolaides KH (2011) Prediction of small-for-gestational age neonates from biophysical and biochemical markers at 11–13 weeks. Fetal Diagn Ther 29: 148–154. https://doi.org/10.1159/000321694 PMID: 21079385

81. Crovetto F, Triulzo S, Crispì F, Rodríguez-Sureda V, Rona E, Domínguez C, et al. (2016) First-trimester screening with specific algorithms for early- and late-onset fetal growth restriction. Ultrasound Obstet Gynecol 48: 340–348. https://doi.org/10.1002/uog.15879 PMID: 26846589

82. Parry S, Sciscione A, Haas DM, Grobman WA, Iams JD, Mercer BM, et al. (2017) Role of early second-trimester uterine artery Doppler screening to predict small-for-gestational age babies in nulliparous women. Am J Obstet Gynecol: 30749–30744.

83. Spencer K, Cowans NJ, Molina F, Kagan KO, Nicolaides KH (2008) First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery. Ultrasound Obstet Gynecol 31: 147–152. https://doi.org/10.1002/uog.5163 PMID: 17992705

84. Antsaklis P, Daskalakis G, Pilialis A, Papantoniou N, Mesogitis S, Antsaklis A (2011) The role of cervical length measurement at 11–14 weeks for the prediction of preterm delivery. J Matern Fetal Neonatal Med 24: 465–470. https://doi.org/10.3109/14767058.2010.501124 PMID: 20608797

85. Bakalis SP, Poon LC, Vayna AM, Paflis I, Nicolaides KH (2012) C-reactive protein at 11–13 weeks’ gestation in spontaneous early preterm delivery. J Matern Fetal Neonatal Med 25: 2475–2478. https://doi.org/10.3109/14767058.2012.171727 PMID: 22900797

86. Gervasi MT, Romero R, Bracalone G, Erez O, Dong Z, Hassan SS, et al. (2012) Midtrimester amniotic fluid concentrations of interleukin-6 and interferon-gamma-inducible protein-10: evidence for heterogeneity of intra-amniotic inflammation and associations with spontaneous early (<32 weeks) and late (>32 weeks) preterm delivery. J Perinat Med 40: 329–343. https://doi.org/10.1515/jpm-2012-0034 PMID: 22752762

87. Greco E, Gupta R, Syngelaki A, Poon LC, Nicolaides KH (2012) First-trimester screening for spontaneous preterm delivery with maternal characteristics and cervical length. Fetal Diagn Ther 31: 154–161. https://doi.org/10.1159/000355986 PMID: 22399065

88. Goetzinger KR, Cahill AG, Kemna J, Odibo L, Macones GA, Odibo AO (2012) First-trimester prediction of preterm birth using ADAM12, PAPP-A, uterine artery Doppler, and maternal characteristics. Prenat Diagn 32: 1002–1007. https://doi.org/10.1002/pd.3949 PMID: 22847849

89. Stout MJ, Goetzinger KR, Tuuil MG, Cahill AG, Macones GA, Odibo AO (2013) First trimester serum analytes, maternal characteristics and ultrasound markers to predict pregnancies at risk for preterm birth. Placenta 34: 14–19. https://doi.org/10.1016/j.placenta.2012.10.013 PMID: 23199792

90. Conde-Aguedelo A, Romero R (2014) Prediction of preterm birth in twin gestations using biophysical and biochemical tests. Am J Obstet Gynecol 211: 583–595. https://doi.org/10.1016/j.ajog.2014.07.047 PMID: 25072738

91. Parra-Cordero M, Sepulveda-Martinez A, Rencore G, Valdés E, Pedraza D, Munoz H (2014) Is there a role for cervical assessment and uterine artery Doppler in the first trimester of pregnancy as a screening test for spontaneous preterm delivery? Ultrasound Obstet Gynecol 43: 291–296. https://doi.org/10.1002/uog.12465 PMID: 23526790

92. Ekin A, Gezer C, Kulhan G, Avci ME, Taner CE (2015) Can platelet count and mean platelet volume during the first trimester of pregnancy predict preterm premature rupture of membranes? J Obstet Gynaecol Res 41: 23–28. https://doi.org/10.1111/jog.12484 PMID: 25130327

93. Quezada MS, Francisco C, Dumitrascu-Biris D, Nicolaides KH, Poon LC (2015) Fetal fraction of cell-free DNA in maternal plasma in the prediction of spontaneous preterm delivery. Ultrasound Obstet Gynecol 45: 101–105. https://doi.org/10.1002/uog.14666 PMID: 25251634

94. Kim SM, Romero R, Lee J, Chaemsalithong P, Lee MW, Chaoyasit N, et al. (2016) About one-half of early spontaneous preterm deliveries can be identified by a rapid matrix metalloproteinase-8 (MMP-8) bedside test at the time of mid-trimester genetic amniocentesis. J Matern Fetal Neonatal Med 29: 2414–2422. https://doi.org/10.3109/14767058.2015.1094049 PMID: 26643648

95. Chaiworapongsa T, Romero R, Korzeniewski SJ, Kusanovic JP, Soto E, Lam J, et al. (2013) Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol 208: 287.e281-287.e215

96. Conde-Aguedelo A, Bird S, Kennedy SH, Villar J, Papageorghiou AT (2015) First- and second-trimester tests to predict stillbirth in unselected pregnant women: a systematic review and meta-analysis. BJOG 122: 41–55. https://doi.org/10.1111/1471-0528.13096 PMID: 25236870
97. Akolekar R, Machuca M, Mendes M, Paschos V, Nicolaides KH (2016) Prediction of stillbirth from placental growth factor at 11–13 weeks. Ultrasound Obstet Gynecol 48: 618–623. https://doi.org/10.1002/uog.17288 PMID: 27854388

98. Aupont JE, Akolekar R, Illian A, Neonakis S, Nicolaides KH (2016) Prediction of stillbirth from placental growth factor at 19–24 weeks. Ultrasound Obstet Gynecol 48: 631–635. https://doi.org/10.1002/uog.17229 PMID: 27854395

99. Familiari A, Scala C, Morlando M, Bhide A, Khalil A, Thilaganathan B (2016) Mid-pregnancy fetal growth, uteroplacental Doppler indices and maternal demographic characteristics: role in prediction of stillbirth. Acta Obstet Gynecol Scand 95: 1313–1318. https://doi.org/10.1111/aogs.13012 PMID: 27588413

100. Akolekar R, Tokunaka M, Ortega N, Syngelaki A, Nicolaides KH (2016) Prediction of stillbirth from maternal factors, fetal biometry and uterine artery Doppler at 19–24 weeks. Ultrasound Obstet Gynecol 48: 624–630. https://doi.org/10.1002/uog.17295 PMID: 27854387

101. Kayode GA, Grobbee DE, Amoakoh-Coleman M, Adeleke IT, Ansah E, de Groot JA, et al. (2016) Predicting stillbirth in a low-resource setting. BMC Pregnancy Childbirth 16: 274. https://doi.org/10.1186/s12884-016-1061-2 PMID: 27649795

102. Khalil A, Morales-Rosello J, Townsend R, Morland M, Papageorghiou A, Bhide A, et al. (2016) Value of third-trimester cerebroplacental ratio and uterine artery Doppler indices as predictors of stillbirth and perinatal loss. Ultrasound Obstet Gynecol 47: 74–80. https://doi.org/10.1002/uog.15729 PMID: 26327300

103. Mastrodimas S, Akolekar R, Yerlikaya G, Tzelepis T, Nicolaides KH (2016) Prediction of stillbirth from biochemical and biophysical markers at 11–13 weeks. Ultrasound Obstet Gynecol 48: 613–617. https://doi.org/10.1002/uog.17289 PMID: 27561595

104. Yerlikaya G, Akolekar R, McPherson K, Syngelaki A, Nicolaides KH (2016) Prediction of stillbirth from maternal demographic and pregnancy characteristics. Ultrasound Obstet Gynecol 48: 607–612. https://doi.org/10.1002/uog.17290 PMID: 27561693

105. Trudell AS, Tuuli MG, Colditz GA, Macones GA, Odibo AO (2017) A stillbirth calculator: Development and internal validation of a clinical prediction model to quantify stillbirth risk. PLoS One 12: e0173461. https://doi.org/10.1371/journal.pone.0173461 PMID: 28267756

106. Madazli R, Kuseyrioglu B, Uzun H, Uludag S, Ocak V (2005) Prediction of preeclampsia with maternal mid-trimester placental growth factor, activin A, fibronectin and uterine artery Doppler velocimetry. Int J Gynaecol Obstet 89: 251–257. https://doi.org/10.1016/j.ijgo.2005.02.008 PMID: 15919391

107. Poon LC, Karagiannis G, Leal A, Romero XC, Nicolaides KH (2009) Hypertensive disorders in pregnancy: screening by uterine artery Doppler imaging and blood pressure at 11–13 weeks. Ultrasound Obstet Gynecol 34: 497–502. https://doi.org/10.1002/uog.7439 PMID: 19827052

108. Conde-Agudelo A, Romero R, James MR (2015) Tests to Predict Preeclampsia In: Taylor RN, Roberts JM, Cunningham FG, Lindheimer MD, Chesley LC, editors. Chesley’s Hypertensive disorders in pregnancy. Fourth Edition. ed. Amsterdam; Boston: Elsevier/AP, Academic Press is an imprint of Elsevier,. pp. 221–251.

109. Ylinиемi A, Makikallio K, Korpimaki T, Kouru H, Marttala J, Ryynanen M (2015) Combination of PAPPA, fhCGbeta , AFP, PI GF, sTNFR1, and Maternal Characteristic in Prediction of Early-onset Preeclampsia. Clin Med Insights Reprod Health 9: 13–20. https://doi.org/10.4137/CMRH.S21865 PMID: 26106266

110. Bruniell VB, Prefumo F (2015) Quality of first trimester risk prediction models for pre-eclampsia: a systematic review. Bjog 122: 904–914. https://doi.org/10.1111/1471-0528.13334 PMID: 25761437

111. Scaccacci E, Crovetto F, Triunfo S, Gratacos E, Figueras F (2017) Validation of a first-trimester screening model for pre-eclampsia in an unselected population. Ultrasound Obstet Gynecol 49: 188–193. https://doi.org/10.1002/uog.15982 PMID: 27257033

112. Guizani M, Valsamis J, Dutemeyer V, Kang X, Ceccoli C, Khalife J, et al. (2017) First-Trimester Combined Multimarker Prospective Study for the Detection of Pregnancies at a High Risk of Developing Preeclampsia Using the Fetal Medicine Foundation-Algorithm. Fetal Diagn Ther: 1–8.

113. Park HJ, Kim SH, Jung YW, Shim SS, Kim JY, Cho YK, et al. (2014) Screening models using multiple markers for early detection of late-onset preeclampsia in low-risk pregnancy. BMC Pregnancy Childbirth 14: 35. https://doi.org/10.1186/1471-2393-14-35 PMID: 24442993

114. Sibai BM, Gordon T, Thom E, Cantis SN, Klebanoff M, McNellis D, et al. (1995) Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol 172: 642–648. PMID: 7856699
115. Sibai BM, Ewell M, Levine RJ, Klebanoff MA, Esterlitz J, Catalano PM, et al. (1997) Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol 177: 1003–1010. PMID: 9396883

116. Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH (2010) Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens 24: 104–110. https://doi.org/10.1038/jhh.2009.45 PMID: 19516271

117. Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH (2015) Competing risks model in screening for preeclampsia by maternal characteristics and medical history. Am J Obstet Gynecol 213: 62–68.

118. Rocha RS, Alves JA, Maia EHM-SB, Araujo Junior E, Peixoto AB, Santana EF, et al. (2017) Simple approach based on maternal characteristics and mean arterial pressure for the prediction of preeclampsia in the first trimester of pregnancy. J Perinat Med.

119. Crisp F, Dominguez C, Lurba E, Martin-Gallan P, Cabero L, Gratacos E (2006) Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol 195: 201–207. https://doi.org/10.1016/j.ajog.2006.01.014 PMID: 16545329

120. Kuc S, Wortelboer EJ, van Rijn BB, Franx A, Visser GH, Schielen PC (2011) Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review. Obstet Gynecol Surv 66: 225–239. https://doi.org/10.1097/OGX.0b013e1822270272 PMID: 21756405

121. Tobinaga CM, Tortori MR, Guevoghianian-Silva BY, Pendeloski KP, Akita PA, Sasa N, et al. (2014) Angiogenic factors and uterine Doppler velocimetry in early- and late-onset preeclampsia. Acta Obstet Gynecol Scand 93: 469–476. https://doi.org/10.1111/aogs.12366 PMID: 24580069

122. Seraval V, Grimpel YI, Meiri H, Blitzer M, Baschat AA (2016) Relationship between first-trimester serum placental protein-13 and maternal characteristics, placental Doppler studies and pregnancy outcome. J Perinat Med 44: 543–549. https://doi.org/10.1515/jpm-2015-0324 PMID: 26910737

123. Spencer K, Yu CK, Cowans NJ, Otigba C, Nicolaides KH (2005) Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn 25: 949–953. https://doi.org/10.1002/pd.1251 PMID: 16086443

124. Spencer K, Yu CK, Savvidou M, Papageorgiou AT, Nicolaides KH (2006) Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free beta-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks’ gestation. Ultrasound Obstet Gynecol 27: 658–663. https://doi.org/10.1002/uog.2676 PMID: 16493628

125. Poon LC, Stratilava V, Piras S, Piri S, Nicolaides KH (2010) Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11–13 weeks. Prenat Diagn 30: 216–223. https://doi.org/10.1002/pd.2440 PMID: 20108221

126. Ay E, Kavak ZN, Elter K, Gokaslan H, Pekin T (2005) Screening for pre-eclampsia by using maternal serum inhibin A, activin A, human chorionic gonadotropin, unconjugated estriol, and alpha-fetoprotein levels and uterine artery Doppler in the second trimester of pregnancy. Aust N Z J Obstet Gynaecol 45: 283–288. https://doi.org/10.1111/j.1479-828X.2005.00412.x PMID: 16029293

127. Akolekar R, Minekawa R, Veduta A, Romero XC, Nicolaides KH (2009) Maternal plasma inhibin A at 11–13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn 29: 753–760. https://doi.org/10.1002/pd.2279 PMID: 19412915

128. Yu J, Shixia CZ, Wu Y, Duan T (2011) Inhibin A, activin A, placential growth factor and uterine artery Doppler pulsatility index in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 37: 528–533. https://doi.org/10.1002/uog.8800 PMID: 20737451

129. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350: 672–683. https://doi.org/10.1056/NEJMoa031884 PMID: 14764923

130. Moore AG, Young H, Keller JM, Ojo LR, Yan J, Simas TA, et al. (2012) Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Matern Fetal Neonatal Med 25: 2651–2657. https://doi.org/10.3109/14767058.2012.713055 PMID: 22861812

131. Villa PM, Hamalainen E, Maki A, Raikkonen K, Pesonen AK, Taipale P, et al. (2013) Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort. BMC Pregnancy Childbirth 13: 110. https://doi.org/10.1186/1471-2393-13-110 PMID: 23663420

132. Allen RE, Rogozinska E, Cleverly K, Aquilina J, Thangaratnam S (2014) Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 182: 194–201. https://doi.org/10.1016/j.ejogrb.2014.09.027 PMID: 25305662

133. Wataganara T, Pratumvinit B, Lahfahrongron P, Pooliam J, Talungchit P, Leetheeragul J, et al. (2017) Circulating soluble fms-like tyrosine kinase-1 and placental growth factor from 10 to 40 weeks’
pregnancy in normotensive women. J Perinat Med 45: 895–901. https://doi.org/10.1515/jpm-2017-0093 PMID: 28665791

134. Luo Q, Han X (2017) Second-trimester maternal serum markers in the prediction of preeclampsia. J Perinat Med 45: 809–816. https://doi.org/10.1515/jpm-2016-0249 PMID: 27935854

135. Wikstrom AK, Larsson A, Eriksson UJ, Nash P, Norden-Lindeberg S, Olovsson M (2007) Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol 109: 1368–1374. https://doi.org/10.1097/AOG.0b013e328043a179 PMID: 17540809

136. Kurtoglu E, Avci B, Kokcu A, Celik H, Cengiz Dura M, Malatayaloglu E, et al. (2016) Serum VEGF and PGF may be significant markers in prediction of severity of preeclampsia. J Matern Fetal Neonatal Med 29: 1987–1992. https://doi.org/10.3109/14767058.2015.1072157 PMID: 26333278

137. Tsiakkas A, Cazacu R, Wright A, Wright D, Nicolaides KH (2016) Maternal serum placental growth factor at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia. Ultrasound Obstet Gynecol 47: 472–477. https://doi.org/10.1002/uog.15816 PMID: 26582455

138. Tsatsaris V, Goffin F, Munaut C, Bricheant JF, Pignon MR, Noel A, et al. (2003) Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 88: 5555–5563. https://doi.org/10.1210/jc.2003-030528 PMID: 14602804

139. Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, et al. (2003) Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 88: 2348–2351. https://doi.org/10.1210/jc.2002-021942 PMID: 12727995

140. Chaiworapongs a T, Romero R, Espinoza J, Bujold E, Mee Kim Y, Goncalves LF, et al. (2004) Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 190: 1541–1547; discussion 1547–1550. https://doi.org/10.1016/j.ajo.2004.03.043 PMID: 15284729

141. Chung JY, Song Y, Wang Y, Magness RR, Zheng J (2004) Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies. J Clin Endocrinol Metab 89: 2484–2490. https://doi.org/10.1210/jc.2003-031580 PMID: 15126581

142. Chaiworapongs a T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, et al. (2005) Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 17: 3–18. https://doi.org/10.1080/1476705040028816 PMID: 15904791

143. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355: 992–1005. https://doi.org/10.1056/NEJMoa055352 PMID: 16957146

144. Stepan H, Geipel A, Schwarz F, Kramer T, Wessel N, Faber R (2008) Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol 198: 175 e171-176.

145. Chaiworapongs a T, Romero R, Kusanovic JP, Mittal P, Kim SK, Gotsch F, et al. (2010) Plasma soluble endoglin concentration in pre-eclampsia is associated with an increased impedance to flow in the maternal and fetal circulations. Ultrasound Obstet Gynecol 35: 155–162. https://doi.org/10.1002/uog.4791 PMID: 20101637

146. Foidart JM, Munaut C, Chantraine F, Ako lekar R, Nicolaides KH (2010) Maternal plasma soluble endoglin at 11–13 weeks’ gestation in pre-eclampsia. Ultrasound Obstet Gynecol 35: 680–687. https://doi.org/10.1002/uog.7621 PMID: 20205159

147. Rana S, Cerdeira AS, Weng er J, Salahuddin S, Lim KH, Ralston SJ, et al. (2012) Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. PLoS One 7: e48259. https://doi.org/10.1371/journal.pone.0048259 PMID: 23110221

148. Lai J, Syngelaki A, Poon LC, Nucci M, Nicolaides KH (2013) Maternal serum soluble endoglin at 30–33 weeks in the prediction of preeclampsia. Fetal Diagn Ther 34: 139–144. https://doi.org/10.1159/000343220 PMID: 23154616

149. De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D’Anna R (2008) Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 87: 837–842. https://doi.org/10.1080/00016340802253759 PMID: 18607829

150. Baumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbek DV (2008) First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 199: 266.e261-266.

151. Kusanovic JP, Romero R, Chaiworapongs a T, Erez O, Mittal P, Vaisbuch E, et al. (2009) A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors
in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 22: 1021–1038. https://doi.org/10.3109/14767050902994754 PMID: 19900040

152. Cindrova-Davies T, Sanders DA, Burton GJ, Charnock-Jones DS (2011) Soluble FLT1 sensitizes endothelial cells to inflammatory cytokines by antagonizing VEGF receptor-mediated signalling. Cardiovasc Res 89: 671–679. https://doi.org/10.1093/cvr/cqv346 PMID: 21139021

153. Aggarwal PK, Chandel N, Jain V, Jha V (2012) The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. J Hum Hypertens 26: 236–241. https://doi.org/10.1038/jhh.2011.29 PMID: 21451568

154. Cim N, Kurdoglu M, Ege S, Yoruk I, Yaman G, Yildizhan R (2016) An analysis on the roles of angiogenesis-related factors including serum vitamin D, soluble endoglin (sEng), soluble fms-like tyrosine kinase 1 (sFlt1), and vascular endothelial growth factor (VEGF) in the diagnosis and severity of late-onset preeclampsia. J Matern Fetal Neonatal Med 1: 1–6.

155. Perales A, Delgado JL, de la Calle M, Garcia-Hernandez JA, Escudero AI, Campillos JM, et al. (2017) sFlt-1/PIGF for prediction of early-onset pre-eclampsia: STEPS (Study of Early Pre-eclampsia in Spain). Ultrasound Obstet Gynecol 50: 373–382. https://doi.org/10.1002/uog.17373 PMID: 27883242

156. O’Gorman N, Nicolaides KH, Poon LC (2016) The use of ultrasound and other markers for early detection of preeclampsia. Womens Health (Lond) 12: 199–207.

157. Rome R, Kuivaniemi H, Tromp G (2002) Functional genomics and proteomics in term and preterm parturition. J Clin Endocrinol Metab 87: 2431–2434. https://doi.org/10.1210/jcem.87.6.8689 PMID: 12050194

158. Rome R, Espinoza J, Gotsch F, Kusanovic JP, Erez O, et al. (2006) The use of high-dimensional biology (genomics, transcriptomics, proteomics, and metabolomics) to understand the preterm parturition syndrome. Bjog 113 Suppl 3: 118–135.

159. Rome R, Tromp G (2006) High-dimensional biology in obstetrics and gynecology: functional genomics in microarray studies. Am J Obstet Gynecol 195: 360–363. https://doi.org/10.1016/j.ajog.2006.06.077 PMID: 16890547

160. Blankley RT, Robinson NJ, Aplin JD, Crocker IP, Gaskell SJ, Whetton AD, et al. (2010) A gel-free quantitative proteomics analysis of factors released from hypoxic-conditioned placenta. Reprod Sci 17: 247–257. https://doi.org/10.1177/1933719109351320 PMID: 19907055

161. Cox J, Mann M (2011) Quantitative, high-resolution proteomics for data-driven systems biology. Annu Rev Biochem 80: 273–299. https://doi.org/10.1146/annurev-biochem-010510-104531 PMID: 21548781

162. Klein J, Buffin-Meyer B, Mullen W, Carty DM, Delles C, Vlahou A, et al. (2014) Clinical proteomics in obstetrics and neonatology. Expert Rev Proteomics 11: 75–89. https://doi.org/10.1586/14789450.2014.872564 PMID: 24404900

163. Hernandez-Nunez J, Valdes-Yong M (2015) Utility of proteomics in obstetric disorders: a review. Int J Womens Health 7: 385–391. https://doi.org/10.2147/IJWH.S79577 PMID: 25926758

164. Edlow AG, Slonim DK, Wick HC, Hui L, Bianchi DW (2015) The pathway not taken: understanding 'omics data in the perinatal context. Am J Obstet Gynecol 213: e51-172.

165. Koliakou A, Stobdan T, Malhotra N, Pasha MA (2008) The genetic aspects of pre-eclampsia: achievements and limitations. Biochem Genet 46: 451–479. https://doi.org/10.1007/s10528-008-9163-9 PMID: 18437552

166. Johnson M, Brennecke S, Iversen AC, East C, Olsen G, Kent J, et al. (2012) OS046. Genome-wide transcriptome directed pathway analysis of maternal pre-eclampsia susceptibility genes. PLoS One 10: e0128230. https://doi.org/10.1371/journal.pone.0128230 PMID: 26010865
171. Sober S, Reiman M, Kikas T, Rull K, Inno R, Vaas P, et al. (2015) Extensive shift in placental transcriptome profile in preeclampsia and placental origin of adverse pregnancy outcomes. Sci Rep 5: 13336. https://doi.org/10.1038/srep13336 PMID: 26268791

172. Whitehead CL, Walker SP, Tong S (2016) Measuring circulating placental RNAs to non-invasively assess the placental transcriptome and to predict pregnancy complications. Prenat Diagn 36: 997–1008. https://doi.org/10.1002/pd.4934 PMID: 27711965

173. Luo S, Cao N, Tang Y, Gu W (2017) Identification of key microRNAs and genes in preeclampsia by bioinformatics analysis. PLoS One 12: e0178549. https://doi.org/10.1371/journal.pone.0178549 PMID: 28594854

174. Ashar-Patel A, Kaymaz Y, Rajakumar A, Bailey JA, Karumanchi SA, Moore MJ (2017) FLT1 and transcriptome-wide polyadenylation site (PAS) analysis in preeclampsia. Sci Rep 7: 12139. https://doi.org/10.1038/s41598-017-11639-6 PMID: 28939845

175. Than NG, Romero R, Tarca AL, Kekesi KA, Xu Y, Xu Z, et al. (2018) Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia. Front Immunol 9: 1661. https://doi.org/10.3389/fimmu.2018.01661 PMID: 30135684

176. Kolla V, Jeno P, Moes S, Lapaire O, Hoesli I, Hahn S (2012) Quantitative proteomic (iTRAQ) analysis of 1st trimester maternal plasma samples in pregnancies at risk for preeclampsia. J Biomed Biotechnol 2012: 305964. https://doi.org/10.1155/2012/305964 PMID: 22570525

177. Myers J, Macleod M, Reed B, Harris N, Mires G, Baker P (2004) Use of proteomic patterns as a novel screening tool in pre-eclampsia. J Obstet Gynaeco 24: 873–874. https://doi.org/10.1586/01443610400018791 PMID: 16147639

178. Webster RP, Myatt L (2007) Elucidation of the molecular mechanisms of preeclampsia using proteomic technologies. Proteomics Clin Appl 1: 1147–1155. https://doi.org/10.1002/prca.200700128 PMID: 21136764

179. Carty DM, Schiffer E, Delles C (2013) Proteomics in hypertension. J Hum Hypertens 27: 211–216. https://doi.org/10.1038/jhh.2012.30 PMID: 22874797

180. Bahado-Singh RO, Akolekar R, Mardal R, Dong E, Xia J, Kruger M, et al. (2012) Metabolomics and first-trimester prediction of early-onset preeclampsia. J Matern Fetal Neonatal Med 25: 1840–1847. https://doi.org/10.3109/14767058.2012.680254 PMID: 22494326

181. Austad M, Tangeras LH, Skrastad RB, Salvesen K, Austgulen R, Iversen AC, et al. (2015) First Trimester Urine and Serum Metabolomics for Prediction of Preeclampsia and Gestational Hypertension: A Prospective Screening Study. Int J Mol Sci 16: 21520–21538. https://doi.org/10.3390/ijms160921520 PMID: 26370975
191. Koster MP, Vreeken RJ, Harms AC, Dane AD, Kuc S, Schielen PC, et al. (2015) First-Trimester Serum Acylcarnitine Levels to Predict Preeclampsia: A Metabolomics Approach. Dis Markers 2015: 857108. https://doi.org/10.1155/2015/857108 PMID: 26146448

192. Benton SJ, Ly C, Vukovic S, Bainbridge SA (2016) Andree Gruslin award lecture: Metabolomics as an important modality to better understand preeclampsia. Placenta: 1–9.

193. de Groot CJ, Guzel C, Steegers-Theunissen RP, de Maat M, Derkx P, Roes EM, et al. (2007) Specific peptides identified by mass spectrometry in placental tissue from pregnancies complicated by early onset preeclampsia attained by laser capture dissection. Proteomics Clin Appl 1: 325–335. https://doi.org/10.1002/prca.200600911 PMID: 25838414

194. Hamamura K, Nonaka D, Ishikawa H, Banzai M, Yanagida M, Nojima M, et al. (2016) Simple quantitation for potential serum disease biomarker peptides, primarily identified by a peptidomics approach in the serum with hypertensive disorders of pregnancy. Ann Clin Biochem 53: 85–96. https://doi.org/10.1177/0004563215583697 PMID: 25838414

195. Kononikhin AS, Starodubtseva NL, Bugrova AE, Shirokova VA, Chagovets VV, Indykina MI, et al. (2016) An untargeted approach for the analysis of the urine peptidome of women with preeclampsia. J Proteomics 149: 38–43. https://doi.org/10.1016/j.jprot.2016.04.024 PMID: 27109351

196. Dai X, Song X, Rui C, Meng L, Xue X, Ding H, et al. (2017) Peptidome Analysis of Human Serum From Normal and Preeclamptic Pregnancies. J Cell Biochem: 1–8.

197. Qian Y, Zhang L, Rui C, Ding H, Mao P, Ruan H, et al. (2017) Peptidome analysis of amniotic fluid from pregnancies with preeclampsia. Mol Med Rep: 7337–7344. https://doi.org/10.3892/mmr.2017.7582 PMID: 28944906

200. Brown SH, Eather SR, Freeman DJ, Meyer BJ, Mitchell TW (2016) A Lipidomic Analysis of Placenta in Preeclampsia: Evidence for Lipid Storage. PLoS One 11: e0163972. https://doi.org/10.1371/journal.pone.0163972 PMID: 27685997

201. Watanabe H, Hamada H, Yamada N, Sohda S, Yamakawa-Kobayashi K, Yoshikawa H, et al. (2004) Proteome analysis reveals elevated serum levels of clusterin in patients with preeclampsia. Proteomics 4: 537–543. https://doi.org/10.1002/pmic.200300565 PMID: 14760726

204. Blankley RT, Gaskell SJ, Whetton AD, Dive C, Baker PN, Myers JE (2009) A proof-of-principle gel-free proteomics strategy for the identification of predictive biomarkers for the onset of pre-eclampsia. Biorxiv 116: 1473–1480. https://doi.org/10.1101/j.1471-0528.2009.02283.x PMID: 19663911

205. Auer J, Camoin L, Guillonneau F, Rigourd V, Chelbi ST, Leduc M, et al. (2010) Serum profile in pre-eclampsia and intra-uterine growth restriction revealed by iTRAQ technology. J Proteomics 73: 1004–1017. https://doi.org/10.1016/j.jprot.2009.12.014 PMID: 20079470

206. Rasenan J, Girsén A, Lu X, Lapidus JA, Standley M, Reddy A, et al. (2010) Comprehensive maternal serum proteomic profiles of preclinical and clinical preeclampsia. J Proteome Res 9: 4274–4281. https://doi.org/10.1021/pr100198m PMID: 20568817

207. Liu C, Zhang N, Yu H, Chen Y, Liang Y, Deng H, et al. (2011) Proteomic analysis of human serum for finding pathogenic factors and potential biomarkers in preeclampsia. Proteome 32: 168–174. https://doi.org/10.1016/j.proteom.2011.07.006 PMID: 21145106

208. Hsu TY, Hsieh TT, Yang KD, Tsai CC, Ou CY, Cheng BH, et al. (2015) Proteomic profiling reveals alpha1-antitrypsin, alpha1-microglobulin, and clusterin as preeclampsia-related serum proteins in pregnant women. Taiwan J Obstet Gynecol 54: 499–504. https://doi.org/10.1016/j.tjog.2014.01.007 PMID: 26522099

209. Koliakos A, Gourgiotis D, Daskalakis G, Marmarinos A, Lykoudi A, Mavrili D, et al. (2015) Validation of serum biomarkers derived from proteomic analysis for the early screening of preeclampsia. Dis Markers 2015: 121848. https://doi.org/10.1155/2015/121848 PMID: 25628472

210. Anand S, Bench Alvarez TM, Johnson WE, Esplin MS, Merrell K, Porter TF, et al. (2015) Serum biomarkers predictive of pre-eclampsia. Biomark Med 9: 563–575. https://doi.org/10.2217/bmm.15.21 PMID: 26079961

211. Kim SM, Cho BK, Kang MJ, Norwitz ER, Lee SM, Lee J, et al. (2016) Expression changes of proteins associated with the development of preeclampsia in maternal plasma: A case-control study. Proteomics 16: 1581–1589. https://doi.org/10.1002/pmic.201500381 PMID: 27001287
210. Kolialexi A, Tsangaris GT, Sifakis S, Gourgiotis D, Katsafadou A, Lykoudi A, et al. (2017) Plasma bio-markers for the identification of women at risk for early-onset preeclampsia. Expert Rev Proteomics 14: 269–276. https://doi.org/10.1080/14789450.2017.1291345 PMID: 28222616

211. Chen G, Zhang Y, Jin X, Zhang L, Zhou Y, Niu J, et al. (2011) Urinary proteomics analysis for renal injury in hypertensive disorders of pregnancy with iTRAQ labeling and LC-MS/MS. Proteomics Clin Appl 5: 300–310. https://doi.org/10.1002/prca.201000100 PMID: 21538910

212. Lee SM, Park JS, Norwitz ER, Kim SM, Kim BJ, Park CW, et al. (2011) Characterization of discriminatory urinary proteomic biomarkers for severe preeclampsia using SELDI-TOF mass spectrometry. J Perinat Med 39: 391–396. https://doi.org/10.1515/JPM.2011.028 PMID: 21576766

213. Kolialexi A, Mavrelidou D, Tounta G, Mavrou A, Papantoniou N (2015) Urine proteomics studies in preeclampsia. Proteomics Clin Appl 9: 501–506. https://doi.org/10.1002/prca.201400092 PMID: 25644222

214. Vascotto C, Salzano AM, D’Ambrosio C, Fruscalzo A, Marchesoni D, di Loreto C, et al. (2007) Oxidized transthyretin in amniotic fluid as an early marker of preeclampsia. J Proteome Res 6: 160–170. https://doi.org/10.1021/pr060315z PMID: 17203960

215. Park JS, Oh KJ, Norwitz ER, Han JS, Choi HJ, Seong HS, et al. (2008) Identification of proteomic biomarkers in amniotic fluid using SELDI-TOF mass spectrometry. Reprod Sci 15: 457–468. https://doi.org/10.1177/1933719108316909 PMID: 18579854

216. Webster RP, Pitzer BA, Roberts VH, Brockman D, Myatt L (2007) Differences in the proteome profile in placenta from normal term and preeclamptic preterm pregnancies. Proteomics Clin Appl 1: 446–456. https://doi.org/10.1002/prca.200600745 PMID: 21136696

217. Sun LZ, Yang NN, De W, Xiao YS (2007) Proteomic analysis of proteins differentially expressed in preeclamptic trophoblasts. Gynecol Obstet Invest 64: 17–23. https://doi.org/10.1159/000098399 PMID: 17199091

218. Jin H, Ma KD, Hu R, Chen Y, Yang F, Yao J, et al. (2008) Analysis of expression and comparative profile of normal placental tissue proteins and those in preeclampsia patients using proteomic approaches. Anal Chim Acta 629: 158–164. https://doi.org/10.1016/j.aca.2008.09.015 PMID: 18940332

219. Gharasei-Fard B, Zolghadri J, Kamali-Sarvestani E (2010) Proteome differences of placenta between pre-eclampsia and normal pregnancy. Placenta 31: 121–125. https://doi.org/10.1016/j.placenta.2009.11.004 PMID: 19954843

220. Centlow M, Hansson SR, Welinder C (2010) Differential proteome analysis of the preeclamptic placenta using optimized protein extraction. J Biomed Biotechnol 2010: 458748. https://doi.org/10.1155/2010/458748 PMID: 19756160

221. Shin JK, Baek JC, Kang MY, Park JK, Lee SA, Lee JH, et al. (2011) Proteomic analysis reveals an elevated expression of heat shock protein 27 in preeclamptic placentas. Gynecol Obstet Invest 71: 151–157. https://doi.org/10.1159/000315162 PMID: 21335933

222. Feng YL, Zhou CJ, Li XM, Liang XQ (2012) Alpha-1-antitrypsin acts as a preeclampsia-related protein: a proteomic study. Gynecol Obstet Invest 73: 252–259. https://doi.org/10.1159/000334820 PMID: 22414876

223. Epiney M, Ribaux P, Arboit P, Irion O, Cohen M (2012) Comparative analysis of secreted proteins from normal and preeclamptic trophoblastic cells using proteomic approaches. J Proteomics 75: 1771–1777. https://doi.org/10.1016/j.jprot.2011.12.021 PMID: 22234358

224. Baig S, Kothandaraman N, Manikandan J, Rong L, Eu KH, Hill J, et al. (2014) Proteomic analysis of human placental syncytiotrophoblast microvesicles in preeclampsia. Clin Proteomics 11: 40. https://doi.org/10.1186/1559-0275-11-40 PMID: 25469110

225. Ma K, Jin H, Hu R, Xiong Y, Zhou S, Ting P, et al. (2014) A proteomic analysis of placential trophoblastic cells in preeclampsia-eclampsia. Cell Biochem Biophys 69: 247–258. https://doi.org/10.1007/s12013-013-9772-4 PMID: 24343450

226. Yang JI, Kong TW, Kim HS, Kim HY (2015) The Proteomic Analysis of Human Placenta with Preeclampsia and Normal Pregnancy. J Korean Med Sci 30: 770–778. https://doi.org/10.3346/jkms.2015.30.6.770 PMID: 25628931

227. Mary S, Kulkarni MJ, Malakar D, Joshi SR, Mehendale SS, Giri AP (2017) Placental Proteomics Provides Insights into Pathophysiology of Pre-Eclampsia and Predicts Possible Markers in Plasma. J Proteome Res 16: 1050–1060. https://doi.org/10.1021/acs.jproteome.6b00955 PMID: 28030762
229. Romero R, Erez O, Maymon E, Chaemsaithong P, Xu Z, Pacora P, et al. (2017) The maternal plasma proteome changes as a function of gestational age in normal pregnancy: a longitudinal study. Am J Obstet Gynecol 217: 67.e61-67.e21.

230. Aghaeepour N, Lehallier B, Baca Q, Ganio EA, Wong RJ, Ghaemi MS, et al. (2018) A proteomic clock of human pregnancy. Am J Obstet Gynecol 218: 347.e34-347.e314.

231. Vettraino IM, Roby J, Tolley T, Parks WC (1996) Collagenase-I, stromelysin-I, and matrilysin are expressed within the placenta during multiple stages of human pregnancy. Placenta 17: 557–563. PMID: 8916203

232. Weiss A, Goldman S, Shalev E (2007) The matrix metalloproteinases (MMPS) in the decidua and fetal membranes. Front Biosci 12: 649–659. PMID: 17127325

233. Reister F, Kingdom JC, Ruck P, Marzusch K, Heyl W, Pauer U, et al. (2006) Altered protease expression by periarterial trophoblast cells in severe early-onset preeclampsia with IUGR. J Perinat Med 34: 272–279. https://doi.org/10.1515/JPM.2006.052 PMID: 16856814

234. Smith SD, Dunk CE, Aplin JD, Harris LK, Jones RL (2009) Evidence for immune cell involvement in decidual spiral arteriole remodeling in early human pregnancy. Am J Pathol 174: 1959–1971. https://doi.org/10.2353/ajpath.2009.080995 PMID: 19349361

235. Li Q, Park PW, Wilson CL, Parks WC (2002) Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111: 635–646. PMID: 12464176

236. Manon-Jensen T, Multhaup HA, Couchman JR (2013) Mapping of matrix metalloproteinase cleavage sites on syndecan-1 and syndecan-4 ectodomains. FEBS J 280: 2320–2331. https://doi.org/10.1111/febs.12174 PMID: 23384311

237. Jokimaa V, Inki P, Kujari H, Hirvonen O, Ekholm E, Anttila L (1998) Expression of syndecan-1 in human placenta and decidua. Placenta 19: 157–163. PMID: 9548182

238. Stepp MA, Pal-Ghosh S, Tadwalkar G, Pajoohesh-Ganj A (2015) Syndecan-1 and Its Expanding List of Contacts. Adv Wound Care (New Rochelle) 4: 235–249.

239. Halpert I, Sires UI, Roby JD, Potter-Perigo S, Wight TN, Shapiro SD, et al. (1996) Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci U S A 93: 9748–9753. https://doi.org/10.1073/pnas.93.18.9748 PMID: 8790402

240. Katahuchi H, Yih S, Ohba T, Matsu K, Takahashi K, Takeya M, et al. (2003) Characterization of macrophages in the decidual atherotic spiral artery with special reference to the cytology of foam cells. Med Electron Microsc 36: 253–262. https://doi.org/10.1007/s00795-003-0223-2 PMID: 16228658

241. Tomer A (2004) Platelet activation as a marker for in vivo prothrombotic activity: detection by flow cytometry. J Biol Regul Homeost Agents 18: 172–177. PMID: 15471223

242. Takagi J, Petre BM, Walz T, Springer TA (2002) Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell 110: 599–511. PMID: 12230977
250. Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E (1986) Platelet membrane glycoprotein Iib/IIIa: member of a family of Arg-Gly-Asp—specific adhesion receptors. Science 231: 1559–1562. PMID: 2420006

251. Janes SL, Goodall AH (1994) Flow cytometric detection of circulating activated platelets and platelet hyper-responsiveness in pre-eclampsia and pregnancy. Clin Sci (Lond) 86: 731–739.

252. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, Rayburn H, Crowley D, Ullman-Cullere M, et al. (1999) Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 103: 229–238. https://doi.org/10.1172/JCI5487 PMID: 9916135

253. Tronik-Le Roux D, Roullot V, Poujol C, Kortulewski T, Nurden P, Marguerie G (2000) Thrombasthenic mice generated by replacement of the integrin alpha(IIb) gene: demonstration that transcriptional activation of this megakaryocytic locus precedes lineage commitment. Blood 96: 1399–1408. PMID: 10942384

254. McKenzie ME, Malinin AI, Bell CR, Dzhanashvili A, Horowitz ED, Oshrine BR, et al. (2003) Aspirin inhibits surface glycoprotein Iib/IIIa, P-selectin, CD63, and CD107a receptor expression on human platelets. Blood Coagul Fibrinolysis 14: 249–253. https://doi.org/10.1097/01.mbc.000046182.72384.ab PMID: 12695747

255. LeFevre ML (2014) Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 161: 819–826. https://doi.org/10.7326/M14-1884 PMID: 25200125

256. ACOG American College of Obstetricians and Gynecologists: Practice advisory on low-dose aspirin and prevention of preeclampsia: updated recommendations. Washington, DC: 2016. https://www.acog.org/About-ACOG/News-Room/Practice-Advisories/Practice-Advisory-Low-Dose-Aspirin-and-Prevention-of-Preeclampsia-Updated-Recommendations.

257. Seidler AL, Askie L, Ray JG (2018) Optimal aspirin dosing for preeclampsia prevention. Am J Obstet Gynecol 219: 117–118. https://doi.org/10.1016/j.ajog.2018.03.018 PMID: 29588190

258. Than N, Romero R, Tarca A, Kekesi K, Xu Y, Juhasz K, et al. (2017) Systems biology identifies key molecular networks and hub factors in placental pathways of preeclampsia. Reproductive Sciences, 24(1 Suppl), 278A.

259. Spencer K, Macri JN, Altken DA, Connor JM (1992) Free beta-hCG as first-trimester marker for fetal trisomy. Lancet 339: 1480.

260. Spencer K (2000) Second-trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome. Prenat Diagn 20: 652–656. PMID: 10951476

261. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH (2008) First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 31: 493–502. https://doi.org/10.1002/uog.5332 PMID: 18432600

262. Colosi E, D’Ambrosio V, Periti E (2016) First trimester contingent screening for trisomies 21,18,13: is this model cost efficient and feasible in public health system? J Matern Fetal Neonatal Med: 1–13.